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Abstract: Ion channel targeted drugs have always been related with either the central nervous system (CNS), the periph-
eral nervous system, or the cardiovascular system. Within the CNS, basic indications of drugs are: sleep disorders, anxi-
ety, epilepsy, pain, etc. However, traditional channel blockers have multiple adverse events, mainly due to low specificity 
of mechanism of action. Lately, novel ion channel subtypes have been discovered, which gives premises to drug discovery 
process led towards specific channel subtypes. An example is Na+ channels, whose subtypes 1.3 and 1.7-1.9 are responsi-
ble for pain, and 1.1 and 1.2 – for epilepsy. Moreover, new drug candidates have been recognized. This review is focusing 
on ion channels subtypes, which play a significant role in current drug discovery and development process. The knowl-
edge on channel subtypes has developed rapidly, giving new nomenclatures of ion channels. For example, Ca2+ channels 
are not any more divided to T, L, N, P/Q, and R, but they are described as Cav1.1-Cav3.3, with even newer nomenclature 
1A- 1I and 1S. Moreover, new channels such as P2X1-P2X7, as well as TRPA1-TRPV1 have been discovered, giving 
premises for new types of analgesic drugs. 
Keywords: ASIC, central nervous system, CNS, KCNQ, ion channels, NMDA, P2X, TRP. 
I. INTRODUCTION 
Ion channels have been always related with drug discov-
ery process. Their types, primarily recognized as Na+, K+, 
Ca2+, Cl-, have been basically associated with neuronal proc-
esses. Therefore, drugs targeted to them influence all organs 
or systems related with neuronal activity: the central nervous 
system (CNS), the peripheral nervous system, and the car-
diovascular system. Within the CNS, basic indications of 
drugs are: sleep disorders, anxiety, epilepsy, pain, etc. 
Due to the fact that many CNS diseases are related to 
variable etiology, many drugs have been developed by in 
vivo screening, where pharmacological tests performed on 
animals resemble a state of disease in a human brain. There-
fore, the drugs reveal selectivity towards certain channel 
types, eg. lamotrigine, a known and quite modern anticon-
vulsant, acts mostly via Na+ and Ca2+ channels.  
Lately, novel ion channel subtypes have been discovered, 
which give premises to drug discovery process which lead 
towards specific channel subtypes. An example is Na+ chan-
nels, whose subtypes 1.3 and 1.7-1.9 are responsible for 
pain, and 1.1 and 1.2 – for epilepsy. Currently hardly any 
drug is specific to a single channel, which contributes to drug 
toxicity. However, new drug candidates have been recog-
nized. 
This review is focusing on ion channels subtypes, which 
play a significant role in current drug discovery and devel-
opment process. Nowadays, there are no specific drugs  
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targeted to a single channel subtype. Moreover, the knowl-
edge on channel subtypes has developed rapidly, giving new 
nomenclatures of ion channels. For example, Ca2+ channels 
are not any more divided into T, L, N, P/Q, and R, but they 
are described as Cav1.1-Cav3.3, with even newer nomencla-
ture 1A- 1I and 1S. Moreover, new channels such as 
P2X1-P2X7, as well as TRPA1-TRPV1 have been discov-
ered, giving premises for new types of analgesic drugs.  
The review has been divided by channels families, sub-
families, and drugs in various stages of development. Struc-
tural diversity of channel subtypes has been shown. The bio-
logical activity of drugs has been described and structure-
activity relationship, where possible, has been commented. 
 
 
Fig. (1). Schematic structure of VGSC. 
 
II. ION CHANNELS 
1. Voltage-gated Sodium Channels 
The voltage-gated sodium channels (VGSCs) are hetero-
meric transmembrane proteins which open in response to 
alteration in membrane potential to provide selective perme-
ability for sodium ions [1]. 
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Volted-gated sodium channels as drug targets in CNS 
disorders were recently deeply reviewed by Mantegazza et 
al. [2], Chahine et al. [3] and Tarnawa et al. [4]. In the cur-
rent review we would like to summarize up to date informa-
tion regarding their use in CNS disorders. 
Sodium channels are built by several subunits. Subunit  
forms a Na+ selective pore. It has molecular mass of 260 
kDa. It consists of four homologous domains (I-IV or D1-
D4), of which each contains six -helical transmembrane 
segments (S1-S6) and one non-helical relatively short reen-
trant segment (SS1/SS2), known also as the P-segment, lo-
cated between S5 and S6. All segments and domains are 
connected by internal or external polypeptide loops (Fig. 2). 
The S4 segments are positively charged due to presence of 
positively charged amino acid residues and their role is to 
initiate the voltage-dependent activation of sodium channels 
by moving outward while influenced by the electric field. 
Therefore, S4 segments serve as voltage sensors. The short 
intracellular loop connecting domains III and IV occlude the 
cytoplasmic end of the pore when channel inactivates. The 
membrane reentrant loops between S5 and S6, which are the 
part of P-segment form the ion selectivity filter and ion path-
way as well as the outer region of the pore. Sodium channels 
possess also one or more -subunits of about 35 kDa [5, 6]. 
The role of -subunits is influencing the properties of -
subunits including modulation of sodium currents. 
Moreover, they function as cell adhesion molecules and play 
role in aggregation, migration as well as cell surface expres-
sion. -subunits typically possess a large extracellular im-
munoglobulin-like N-terminal domain, a single transmem-
brane region and intracellular C-terminal region. - and -
subunits are associated non-covalently (  with 1 or 3) or 
covalently, e.g. by means of disulfide bond (  with 2 or 4) 
[6, 7].  
There are at least three functional states of sodium chan-
nels (Fig. 3). The “resting” (closed, activateable) state 
emerges from conformational change that requires repolari-
zation of the membrane (membrane potentials below -60 
mV). In that state the channels are ready to open. In response 
to membrane depolarization they become “open” (or “acti-
vated”) and allow rapid influx of sodium ions. Then they are 
converted to “inactivated”, when the channels undergo con-
formational changes in which isoleucine, phenylalanine, and 
methionine between domains III and IV play an important 
role. When inactivation takes a time of around 1 ms it is 
called “fast-inactivation” and channels shift into a fast-
inactivated state. On the other hand, some channels undergo 
slow-inactivation, which takes considerably longer time 
(seconds to minutes). As a result “slow-inactivation” state, a 
fourth possible functional state is created [1, 6].  
Moreover, functional changes and increased permeability 
of Na+ ions result in generation of sodium currents, which 
can be measured. Those currents are responsible for the up-
stroke of action potential. Many neurons possess two types 
of sodium currents: transient and persistent. Transient Na+ 
current (INaT) is related with opening of the channel when 
sodium ions passively move through the channel on the basis 
of its electrochemical gradient [8]. On the other hand, persis-
tent Na+ current (INaP) is a small slowly inactivating sodium 
current with relatively long kinetics of inactivation (tens of 
seconds), which appears when inactivation of channels is 
incomplete [2]. It activates as potentials close to or slightly 
more negative than resting membrane potential and hardly 
inactivates. Its amplitude is relatively small, it constitutes 
about 1% of the peak amplitude of the transient sodium cur-
rent [8, 9]. 
First classification of sodium channels divided them into 
two groups, either sensitive or non-sensitive to the puffer 
fish toxin, tetrodotoxin (TTX). The existing names of volt-
age-gated sodium channels are derived from the kind of -
subunit that have been cloned. Channels named as NaV1.1 to 
NaV1.9 refer to proteins and differ in functional form of -
subunit. Moreover, a unique -subunit known as NaX has 
been also recognized. The subunit is lacking amino acids 
needed for proper voltage gating and it has been shown to be 
gated by extracellular sodium concentration [6]. TTX-
resistance is characteristic for NaV1.5, NaV1.8 and NaV1.9 
(blockade in micromolar concentration), while NaV1.1,
 
Fig. (2). Schematic arrangement of the -and -subunits of the VGSC. The pore is colored in red, the voltage sensors are yellow [according 
to: 2, 5]. 
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Fig. (3). Action potential of neuronal membrane in different functional states of VGSC. 
 
NaV1.4, NaV1.6 and Nav1.7 are sensitive to nanomolar con-
centrations of TTX [6]. Expression of different subtypes 
shows cell and tissue specificity (Table 1).  
Names SCN1A-SCN5A and SCN8A-SCN11A refer to 
genes which code proteins building different -subunits of 
sodium channels, and SCN6A/SCN7A codifies Nax subunit 
[2]. SCN1B-SCN4B are genes responsible for encoding of -
subunit, 1- 4, respectively [7]. SCN1B is expressed as two 
splice variants, 1 and 1B, both characteristic for human 
brain and heart [10]. Four sodium channel genes are primar-
ily expressed in CNS: SCN1A, SCN2A, SCN3A, and 
SCN8A [11].  
Epilepsy 
Epilepsy is one of the most common neurological disor-
der. In general, it is a tendency to the occurrence of unpro-
voked epileptic seizures which are a result of synchronous 
discharges of large number of neurons [19, 20]. It is now 
known that abnormal expression or function of VGSCs may 
be involved in the pathophysiology of both acquired and 
inherited epilepsy [2]. Great evidence of the role of some 
Table 1. Localization of Different Types of Voltage-gated Sodium Channels in Human Organism 
Type of Sodium 
Channel -Subunit 
Human Gene Localization Disease 
NaV1.1 SCN1A Brain: neuronal somata, proximal dendrites [2, 12] Epilepsy 
NaV1.2 SCN2A 
Brain: predominantly along axons: unmyelinated and myelinated [2], axon 
initial segments [13] 
Epilepsy 
NaV1.3 SCN3A 
Brain: neuronal somata, proximal dendrites; [2, 12], upregulated expression in 
epileptic hippocampal neurons [14] 
Epilepsy, 
Central neuropathic pain [15] 
NaV1.4 SCN4A Skeletal muscle [2]  
NaV1.5 SCN5A Cardiac muscle; some neurons [2], microglial cells [16] 
Atrial fibrillation, ventricular 
fibrillation [10] 
NaV1.6 SCN8A 
Brain: axon initial segments, nodes of Ranvier, neuronal somata, dendrites of 
projection neurons [2] proximal dendrites [12], unmyelinated and myelinated 
axons [17] 
Ataxia 
NaV1.7 SCN9A 
NaV1.8 SCN10A 
NaV1.9 SCN11A 
Peripheral primary sensory neurons [2] 
Trigeminal ganglion neurons [18] 
Neuropathic pain 
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VGSCs in epileptogenesis emerges from the identification of 
several mutations in VGSCs genes leading to inherited epi-
leptic syndromes. Some examples are listed in (Table 2). 
 
Table 2. Epilepsy Syndromes As Result of Mutations in So-
dium Channels Genes 
Gene with 
Mutation 
Epilepsy Syndrome 
SCN1A 
Severe myoclonic epilepsy of infancy (SMEI) [21] 
Generalized epilepsy with febrile seizures  
plus (GEFS+) [21] 
Benign febrile seizures (FS) [13] 
SCN2A 
Benign neonatal-infantile familial seizures (BNIFS) [11] 
Generalized epilepsy with febrile seizures  
plus (GEFS+) [11] 
Idiopathic generalized epilepsy [22] 
SCN1B 
Severe myoclonic epilepsy of infancy (SMEI) [10] 
Generalized epilepsy with febrile seizures  
plus (GEFS+) [10] 
Childhood absence epilepsy [22] 
Temporal lobe epilepsy [22] 
 
The disease in also thought to be associated with signifi-
cantly increased persistent Na+ current, 2-5 times larger than 
under physiological conditions, which is observed in models 
of temporal lobe epilepsy and in neurons obtained from the 
resected temporal lobe of epileptic patients [2]. This current 
may result in enhancing of synaptic potentials, generation of 
subthreshold oscillations, facilitation of repetitive firing, and 
prolongation of depolarized potentials [23]. Persistent so-
dium current is especially interested when observed in neo-
cortical pyramidal neurons [24]. 
For any compound, including sodium channel blockers, 
anticonvulsant activity is not possible without penetration of 
blood-brain barrier, because chemical molecule must reach 
its target NaV1.1, NaV1.2, NaV1.3, and/or NaV1.6 channels 
localized in brain [12, 11]. Moreover, state-dependent affin-
ity to open and/or inactivated channels is beneficial with 
respect to pathomechanism of epilepsy. Thus, anticonvul-
sants possess little effect on normal brain activity but affect 
pathological discharges during seizures. Inhibition of open 
and/or inactivated channels results in strong delaying the 
recovery from that state and reduction of sodium conduc-
tance [25]. Sodium channel blockers used as antiepileptic 
drugs do not show significant species or subtypes differences 
in their potency, which may be result of highly conserved 
nature of the binding site of those drugs [12]. Phenytoin and 
carbamazepine belong to antiepileptic drugs (AEDs) which 
exert their action mainly through inhibition of Na+ current. 
Their clinical efficacy in partial and generalized tonic-clonic 
seizures and lack of activity against absence seizures stay in 
agreement with their activity profile in animal seizure mod-
els. They are effective in maximal electroshock seizure 
(MES) test which is thought to be a predictive model for 
generalized tonic-clonic seizures, but they are not active in 
subcutaneous pentetrazole test (scMet) which is considered 
as predictive for drug’s activity against nonconvulsive sei-
zures [22, 26]. On the other hand, many currently used AEDs 
have a mixed mechanism of action and sodium channels 
inhibition or modulation only accompanies influencing addi-
tional targets in brain. Those drugs are clinically effective 
against different types of seizure. There are still many con-
cerns about contribution of VGSCs inhibition to their anti-
convulsant efficacy [26]. Valproic acid (2-propylpentanoic 
acid) (Fig. (4) may serve as an example. It is a one of the 
most widely used AEDs in the treatment of generalized and 
partial seizures both in adults and children [27]. Several 
studies reported its possibility of reducing sodium currents in 
neocortical rat neurons (at concentration 0.2-2mM) [28], and 
especially persistent Na+ current (with high potency IC50 of 
13.87±0.36 M) [24] as well as in recombinant human 
NaV1.2 channels (IC50 514 M) [12]. The proposed mecha-
nism of VGSCs alteration is that valproate, being a fatty 
acid, may modulate the channels by influencing the bio-
physical properties of the channel’s membrane but it does 
not explain the whole activity [27, 29]. 
 
 
Fig. (4). Chemical structure of valproic acid. 
Neuronal Cell Damage (Neurodegeneration) 
Neuronal cell damage may be caused among others by 
hypoxia which appears in case of decreased or interrupted 
oxygen delivery. Persistent sodium current was identified as 
early and fundamental event in hypoxia. Other mechanisms 
involved in central axons injury are Na+-K+ ATPase failure 
and K+ efflux. As a result, increased concentration of sodium 
ions as well as depolarization of cell membrane were ob-
served, among other in rat hippocampal neurons [30, 31]. 
Raised level of Na+ concentration triggers action of the 
Na+/Ca2+ exchanger (Fig. 5). As a consequence Ca2+ concen-
tration significantly increases generating Ca-dependent in-
jury mechanism. Thus, drugs which inhibit persistent sodium 
current might reduce cell damage in CNS neurons during 
ischaemia or hypoxia, be means of secondary decreasing of 
Ca2+ concentration in cells [9].  
 
 
Fig. (5). Raised Ca2+ concentration in cell as a consequence of in-
creased Na+ influx. 
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NaV1.6 were found to produce larger sodium persistent 
current than other types of sodium channels which may be 
responsible for increasing action of the Na+/Ca2+ exchanger. 
As a result, injury of demyelinated axons in spinal cord is 
likely to occur [17]. Persistent sodium current may also con-
stitute an important factor contributing to neuronal damage 
in Amyotrophic Lateral Sclerosis (ALS) [32]. It is worth to 
mention that multiple sclerosis (MS), a prototypical white 
matter disorder is not only neuroinflammatory condition but 
may be also caused by mitochondrial dysfunction and its 
molecular mechanism of tissue damage is similar to that of 
hypoxic CNS injury. It has been proposed that neuroprotect-
ing agents designed for ischemia may be effective in MS as 
adjuvant therapeutics [33]. Increased influx of sodium ions 
into the cells has been also postulated as a key early event in 
the pathogenesis of secondary traumatic central nervous sys-
tem injury. Some VGSCs blockers like phenytoin, or riluzole 
showed neuroprotective activity in many experimental spinal 
cord injury studies in aspects of motor, neurobehavioral and 
histopathological recovery [34].  
Migraine 
Migraine is a common episodic CNS disorder, which is 
characterized by recurrent attacks of disabling headaches and 
associated symptoms [35]. Several sodium channels blockers 
have been implicated in the therapy of migraine, however, 
their precise mechanism of action in that condition is not 
fully understood [2]. It is generally accepted that inhibition 
of sodium currents can decrease cortical hyperexcitability 
predisposing to migraine. Some hypotheses say also that 
VGSCs blockers may influence cortical spreading depression 
(CSD), defined as slowly propagating wave of neuronal and 
glial depolarization. There is growing evidence that migraine 
aura and headache are triggered by CSD. Moreover, familial 
hemiplegic migraine, an autosomal dominant migraine syn-
drome, may be caused among others by mutation in SCN1A 
gene [36]. 
Neuropathic Pain 
Neuropathic pain is a kind of pain caused by functional 
abnormality of neurons, related with their damage [37]. 
Voltage-gated sodium channels located in peripheral sensory 
neurons play an important role in its pathophysiology be-
cause of their hyperexcitability and generation of spontane-
ous action potential firings. Blockade of VGSC contributes 
to analgesic activity [38]. Most beneficial in pharmacother-
apy of neuropathic pain could be some selective NaV1.7, 
NaV1.8 or NaV1.9 channels blockers, till now not available at 
the pharmaceutical market. In that situation non-selective 
blockers are used which were initially evaluated in different 
disorders e.g. epilepsy [37]. NaV1.3 sodium channels have 
also been implicated in peripheral neuropathic pain. They are 
expressed at relatively high level in rat embryonic dorsal root 
ganglion (DRG) neurons but in adult rodent their expression 
in DRG is very limited [39]. However, after either chronic 
inflammation or nerve injury they are upregulated in second-
order dorsal horn sensory neurons. These findings suggest 
that NaV1.3 might be related with central neuropathic pain 
[39, 40]. Thus not only NaV1.7, NaV1.8 or NaV1.9 blockers, 
but also NaV1.3 blockers may be used in the treatment of 
neuropathic pain.  
Ataxia 
Ataxia is another condition associated with sodium chan-
nels, and more specific with NaV1.6. The reason of that as-
sumption rose form genetic studies which showed that muta-
tions in mice Scn8a gene result in a variety of symptoms 
ranging from mild ataxia to dystonia, paralysis, and juvenile 
lethality [41]. Other research proved the role of their muta-
tions in epileptic syndromes. They might serve as genetic 
modifiers of SMEI and GEFS+ [11]. Studies in human ge-
nome selected one mutation in the SCN8A gene expressed 
NaV1.6 channels which may be responsible for motor and 
cognitive deficits of variable expressivity. This heterozygous 
null mutation leads to cerebellar atrophy, ataxia and mental 
retardation, but an epileptic phenotype in humans was not 
seen [42]. Selective ligands for NaV1.6, if arise, may find a 
place among therapeutics for ataxia.  
Sodium Channels/Sodium Currents Blockers 
Sodium channel blockers were used in therapy even be-
fore their pharmacological targets had been identified or 
cloned. For example, the first local anaesthetic agent, co-
caine, was introduced in 1884 for perioperative analgesia [6]. 
With the development of science, detailed information about 
structure of sodium channels has become available. At first, 
simple models were derived, showing how subunits are em-
bedded in membrane (see (Fig. 2)), then schematic pore-
forming regions were created using known potassium chan-
nels as model channel [1]. Finally, crystal structure of Arco-
bacter butzleri voltage-gated sodium channel (NaVAb) was 
obtained [43, 44]. Parallel with structural studies on sodium 
channels, functional assays have been developed. For that 
purpose, cloning of individual sodium channels, including 
human recombinant, both wild-type or even mutant, in dif-
ferent cell lines have been implicated. That enabled detailed 
studies on targeting a particular population of channels. 
Moreover, many technologies have been implicated to inves-
tigate biological properties of sodium channels blockers, e.g. 
radioligand binding assays, radioactive flux assays, fluores-
cence-based assays, usage of voltage-sensitive dyes [1]. Sev-
eral binding sites on VGSCs have already been identified. 
Sodium channels are the molecular target of many neurotox-
ins which may serve as tools in studying the function and the 
structure of channels. For example, tetrodotoxin and saxi-
toxin bind to site 1 (domains I SS2-S6, II SS2-S6, III SS2-
S6, and IV SS2-S6), batrachotixin, veratridine and aconitine 
to site 2 (domain IS6), -scorpion toxins to site 3 (I S5-S6), 
-scorpion toxins to site 4, DDT site 7, last but not least, 
common anticonvulsants and local anesthetics bind to site 9. 
Binding to specific site of the receptor is related with a de-
fined physiologal effect, direct affecting of ion transport is 
characteristic for sites 1 and 9 and modification of gating 
process with sites 2-8 [5]. Phenytoin, carbamazepine and 
lamotrigine, despite different chemical structures, seem to 
bind to the same site of the receptor. The model of interac-
tion is bimolecular which means one-to-one binding process. 
Moreover, anticonvulsant drug action’s site is thought to be 
located on the extracellular side of channel [45]. Molecular 
modeling has been also implicated in evaluation of binding 
of different sodium channels blockers but it uses homology 
models with other voltage-gated ion channels: calcium and 
potassium [25, 46]. Both molecular modeling and site-
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directed mutagenesis studies helped in indentifying residues 
which are important for binding to the channel (Fig. (6). A 
pharmacophore model of the AED binding to VGSCs sug-
gests that presence of aromatic ring and polar amide, imide 
or amine group in special spatial arrangement is required 
[46]. In the field of sodium currents research invention of 
whole-cell patch clamp recordings enabled measurement of 
transient and persistent currents and thus activity of particu-
lar compounds on specific currents.  
 
 
Fig. (6). Simple presentation of binding sites of AEDs acting as 
sodium channels blockers in the NaV1.2 homology model [46]. 
Aromatic ring has an aromatic-aromatic interaction with Tyr-1771, 
and amide, imide or amine moiety interacts with the aromatic ring 
of Phe-1764 by a low-energy amino-aromatic bond. 
 
Currently, sodium channels blockers serve as drugs in 
several common disorders. They are also extensively inves-
tigated, especially with respect to their selectivity. Many 
sodium channels blockers are state-dependent which means 
that they have preferential affinity for the open and/or inacti-
vated channel’s state when compared to its resting state [6]. 
The same situation refers to both anticonvulsant drugs as 
well as local anesthetics. Although both groups significantly 
differ in chemical structure, they seem to bind to the same 
site of the channel’s pore with similar affinity showing dif-
ferent therapeutic effect [46]. VGSCs blockers act through 
different sites of -subunit, no drugs are known to interact 
directly with -subunit [1]. 
Phenytoin (PHT) 
Phenytoin (5,5-diphenylhydantoin), while tested in ani-
mals is active in MES test but not in scMet [26]. It is consid-
ered as a prototype sodium channel blocker among antiepi-
leptic drugs. PHT preferentially binds to fast-inactivated 
rather than to the resting sodium channels [45], which has a 
beneficial role in inhibition of action potential spread.  
Preclinical evaluation showed also beneficial role of 
phenytoin in mice model of multiple sclerosis – experimental 
autoimmune encephalomyelitis (EAE). Administration of 
PHT provided improved clinical status, preservation of ax-
ons, enhanced action potential conduction and reduced im-
mune infiltrates, so it definitely acted as neuroprotectant 
[47].  
It is been shown that PHT binds to inactivated VGSCs 
with Ki 7 M (tested in rat hippocampal neurons) [48] and 
19 M (tested in wild type sodium channels expressed in 
Xenopus oocyte) [49]. 
Molecular docking to NaV1.2 channel using homology 
model with crystal structures of potassium channels, showed 
that it might bind to the site located in domain IV-S6. Aro-
matic ring is responsible for aromatic-aromatic interaction 
with Tyr-1771, and polar amide or imide group interacts 
with the aromatic ring of Phe-1764 by a low-energy amino-
aromatic hydrogen bond [46]. Several phenytoin derivatives 
have been synthesized and evaluated for affinity to Na+ 
channels [50] resulting in conclusion that the second aro-
matic ring in position 5 is not obligatory for VGSCs binding, 
it can be replaced with aliphatic pentyl, hexyl or heptyl 
chain. Moreover, phenytoin is effective in partial and gener-
alized tonic-clonic seizures but not nonconvulsive seizures 
[26]. 
 
 
Fig. (7). Chemical structure of phenytoin. 
 
Carbamazepine (CBZ) 
Carbamazepine (5H-dibenzo[b,f]azepine)-5-carboxa 
mide) Fig. (8) is and old AED, developed in late 1950s - 
1960s. While tested in vivo CBZ showed effectiveness in 
MES test (ED50s 7.81 mg/kg b.w. (body weight) mice, i.p. 
and 17 mg/kg b.w. mice p.o.) as well as amygdala-kindled 
rats model but it did not show activity in subcutaneous pen-
tetrazole test [26, 37]. 
 
 
Fig. (8). Chemical structure of carbamazpine. 
 
Although well established position in pharmaceutical 
market, its mechanism of action is not yet completely under-
stood. One of the fact is that it inhibits VGSCs in a voltage-
dependent and frequency-dependent manner [2]. It has 
higher affinity to fast-inactivated that to resting VGSC. CBZ 
also blocked persistent Na+ current in concentration depend-
ent manner in NaV1.3 channels expressed in HEK293 cells 
with EC50 16±4 M and maximum block (Emax) 46±4%. In-
activation of persistent sodium current seems to be parallel 
with inhibition of transient Na+ current [8]. Molecular mod-
eling showed that the pharmacophore segments of CBZ and 
PHT are similar, and CBZ is also able to develop interaction 
with binding site in domain IV-S6 [46].  
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CBZ is used in the treatment of simple partial, complex 
partial and generalized tonic-clonic seizures but it is not ef-
fective against absence seizures [26, 37].  
Eslicarbazepine Acetate (ESL) 
Eslicarbazepine acetate ((S)-(-)-10-acetoxy-10,11-dihyd 
ro-5H-dibenz[b,f]azepine-5-carboxamide, BIA 2-093) (Fig. 
9) is an AED second-generation to carbamazepine. It showed 
efficacy in several animal seizure models both electrically 
(MES) and chemically (pentetrazole, bicuculline, picrotoxin, 
4-aminopyridine) evoked [51].  
 
 
Fig. (9). Chemical structure of eslicarbazepine acetate. 
 
Although its precise mechanism of action is not yet ex-
plained, ESL proved to inhibit Na+ current in a voltage-
dependent manner while tested in NIE-115 mouse neuroblas-
toma cells. It preferably binds to VGSCs in inactivated state 
what may result in limitation of repetitive firing and seizure 
spread. In tests performed in rat brain membranes ESL bonds 
in a competitive manner to neurotoxin site 2 of the channel, 
but not site 1, with IC50 of 222 M (138-358) in displacing 
3H-BTX [52]. ESL has been licensed in Europe (not in the 
USA) as adjunctive treatment for partial seizures with or 
without secondary generalization in adults [53].  
Lamotrigine (LTG) and Related Compounds 
Lamotrigine (6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-
diamine) Fig. (10) proved efficacy in several animal seizure 
test: MES, 6Hz test, corneal kindled mice, hippocampal kin-
dled rats, sound induced seizures. Its mechanism of action 
involves inhibition of sodium and calcium channels [22, 37].  
 
 
Fig. (10). Chemical structure of lamotrigine. 
 
Common pharmacophore concept for PTH enables to 
chose elements in the structure of LTG responsible for bind-
ing to the receptor site IV-S6. They are phenyl ring and 
amino group in position five of the triazine, which is moved 
from aromatic ring at the distance of three chemical bonds 
[46]. The binding affinity of LTG to rat brain NaV1.2 ex-
pressed in Xenopus oocytes in inactivated state was reported 
to be 31.9 M [54] while compound’s affinity to the closed 
state of the channel was very low (IC50 641 M; inhibition of 
peak current at - 90 mV in human NaV1.2 -subunit ex-
pressed in Chinese hamster ovary (CHO) cells) [55]. Many 
compounds with LTG related structure were synthesized. 
Examples of three, which had markedly different biological 
properties, helped in explanation of relationship of binding 
site of sodium channel with pharmacological effects. All 
compounds blocked sodium channel in a voltage-dependent 
manner but differed in their affinities for inactivated sodium 
channels (Table 3). By means of assays with mutant sodium 
channels it was proved that all compounds bind to site lo-
cated in S6 in domain IV, and more detailed to amino acid 
residues 1764, 1771 and in some extents also 1760. In fact, 
1764 seems to be essential in voltage-dependent sodium 
channel blocking, whereas interaction with other residues is 
more variable [54].  
JZP-4 
JZP-4 (3-(2,3,5-trichloro-phenyl)-pyrazine-2,6-diamine) 
Fig. (11) is a second generation drug to lamotrigine, with 
only slightly altered structure. It possesses broad spectrum of 
anticonvulsant activity in preclinical evaluation (MES, rat 
hippocampal and amygdala kindling, 6 Hz). It has inhibitory 
effect on both sodium and calcium channels [56]. 
Tests on human NaV1.2 sodium channels proved its volt-
age- and use-dependent inhibition, as well as possibility of 
hyperspolarizing shift in the inactivated state. IC50 values for 
JZP-4 were 165 and 6 M at 90 and 60mV, respectively. 
While tested in NaV1.3 its IC50 were 333, 43 and 7 M at 
120, 90 and 70mV, respectively. In addition to the effect 
on NaV1.2A and 1.3 channels, JZP-4 also showed a weaker 
inhibition of NaV1.8/1.9 from rat dorsal root ganglia tissue. 
JZP-4 is in the Phase II of clinical evaluation in epilepsy.  
Lacosamide (LCM) 
Lacosamide ((2R)-2-acetylamido-N-benzyl-3-methoxy 
propanamide; formerly harkoseride) Fig. (12) demonstrates 
broad anticonvulsant activity in several seizure models, like 
maximal electroshock seizure (MES) test, hippocampal kin-
dling, audiogenic seizures, self-sustaining status epilepticus 
(SSSE), amygdala kindling, and 6 Hz test. Activity in 6-Hz 
test is unlike for other AEDs affecting sodium channels [57]. 
Lacosamide does not exhibit high-affinity for a range of 
receptors and ion channels. However, it showed weak affin-
ity for site 2 of rat cortex VGSC (displacement of [3H]-
batrachotixin – 25% of inhibition at 10 M). After further 
test, it was proved that LCM’s anticonvulsant and analgesic 
effects are due to attenuation of Na+ currents. Lacosamide 
tested in recombinant human NaV1.3 and NaV1.7 sodium 
channels possessed higher affinity for inactivated channels 
than for resting but still less than carbamazepine. In contrary 
to other AEDs like carbamazepine, LCM probably affects 
sodium channel slow inactivation with no effect on fast inac-
tivation. This is a unique mechanism of action which results 
in preferentially block the electrical activity of neurons that 
are chronically depolarized but not those possessing more 
normal resting potentials [15, 58].  
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Table 3. Binding Affinities, Pharmacological Properties and Proposed Biding Sites of LTG and Similar Compounds [54] 
 
KD [ M] Rat Brain Na
+
 Channels 
(NaV1.2) Expressed in Xenopus oo-
cytes in Inactivated State (- 50 mV) 
Pharmacological Proper-
ties in Preclinical Evalua-
tion 
Position of Amino Acid Residues in IV- 
S6 Binding Site 
NN
NH2
NH2
ClCl
NH2
 
17.3 
Analgesic but no anticonvul-
sant activity 
1764 – strong interaction 
1771 – strong interaction 
1760 – weaker interaction 
NN
NH2
Cl
NH2
Cl
F
 
3.7 
Analgesic and anticonvul-
sant activity 
1764 – much stronger interaction; 
1771 – modest interaction; 
1760 weaker interaction 
NN
NH2
N
Cl
Cl
Cl
N
CH3  
10.3 
Prevention of neuronal  
toxicity following stroke 
1764 – strong interaction; 
1771 – weak interaction; 
1760 – weak interaction; 
Possible interactions with amino acid 
Residues in other transmembrane segments 
 
 
Fig. (11). Chemical structure of JZP-4. 
 
 
 
Fig. (12). Chemical structure of lacosamide. 
 
LCM has been licensed for the treatment of partial-onset 
seizures. It has properties that may be also useful for a broad 
range of neuropathic pain patients e.g. in painful diabetic 
neuropathy [15, 57]. 
Topiramate (TPM) 
Topiramate (2,3:4,5-bis-O-(1-methylethylidene)- -D-fruc 
topyranosesulfamate) Fig. (13) exerts its antiepileptic activ-
ity by means of different mechanisms of action like VGSCs 
blockage, potentiation of GABAergic transmission, and 
AMPA receptor sites modulation. It shows relatively broad 
spectrum of anticonvulsant properties in animal studies like 
MES (mice and rats), genetically seizure-prone DBA/2 mice, 
amygdala kindled rats. Topiramate is inactive/weakly active 
in chemically-induced seizure models including pentetrazole, 
picrotoxin, bicuculline, strychnine [59].  
It was proved that TPM blocks persistent Na+ current in 
NaV1.3 expressed in HEK293 cells with EC50 61±37 nM and 
maximum block Emax 30±4%. At the same time, its ability to 
shift transient sodium current to negative potentials is much 
lower (ED50 3.2 M). This finding suggests that topiramate 
acts mainly by means of inhibition of persistent Na+ current 
on the contrary to popular AEDs like carbamazepine and 
phenytoin, which inhibit mainly transient Na+ current [8]. Its 
clinical indication is the management of refractory partial 
and secondarily generalized seizures [59]. At the doses of 25 
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up to 100 mg/day TMP was also approved for prophylaxis of 
migraine [60]. 
 
 
Fig. (13). Chemical structure of topiramate. 
Carisbamate 
Carisbamate (S-2-O-carbamoyl-1-o-chlorophenyletanol, 
RWJ-333369) Fig. (14) showed a broad spectrum of activity 
in preclinical anticonvulsant evaluation, like in MES, 
scMET, bicuculine picrotoxin induced seizures, and audio-
genic seizures. Moreover, it proved efficacy in amygdala 
kindled rats and lamotrigine-resistant kindled rats. Its pro-
posed mechanism of action includes inhibition of VGSCs 
and modest inhibition of calcium channels [56, 22].  
Carisbamate showed a concentration-, voltage- and use-
dependent inhibition of rat NaV1.2 expressed in CHL1610 
cells, with an IC50 value of 68 M (at 67mV). In rat hippo-
campal neurons, carisbamate similarly blocked VGSCs, with 
an IC50 value of 89 M (at 67mV), and inhibited repetitive 
firing of action potentials in a concentration-dependent man-
ner (by 46% at 30 M and 87% at 100 M) [61]. 
 
 
Fig. (14). Chemical structure of carisbamate. 
Rufinamide 
Rufinamide (1-(2,6-difluoro-phenyl)methyl-1H-1,2,3-tria 
zole-4-carboxamide, CGP 33101) (Fig. 15) showed activity 
in MES and pentetrazole-induced test in rodents, as well as 
in bicuculline- and picrotoxin clonus in mice [53].  
 
 
Fig. (15). Chemical structure of rufinamide. 
 
Modulation of sodium channels seems the main mecha-
nism of action of that compound. At concentration 1 M or 
higher it inhibited VGSCs recovery from inactivation in cor-
tical neurons from immature rats. With EC50 of 3.8 M it 
limited sustained repetitive firing of sodium dependent ac-
tion potentials [62]. 
Rufinamide is available in Europe and the USA as effica-
cious and well-tolerated adjunctive treatment for patients 
with partial seizures and Lennox-Gastaut syndrome [53]. 
Flunarizine (FLN) 
Flunarizine ((E)-1-[bis(4-fluorophenyl)methyl]-4-(3-phe 
nyl-2-propenyl)piperazine) Fig. (16) acts by means of vari-
ous mechanisms of action although not yet fully understood 
[63]. Recently it has been proved that the compound effi-
ciently blocks cortical neuronal sodium current in a concen-
tration- and use-dependent manner with IC50 value of 0.94 
M. Moreover, it delays the recovery from fast inactivated 
state INa. This finding suggests that inhibition of sodium 
current which can decrease cortical hyperexcitability may 
may be one of the brain targets of FLN [64]. It antagonizes 
T-type calcium channels, exhibiting affinity towards N-type 
channels of IC50=0.08 M and towards L-type with 
IC50=0.31 M [65]. Flunarizine has been successfully used 
for migraine prophylaxis [63]. 
 
 
Fig. (16). Chemical structure of flunarizine. 
Riluzole 
Riluzole (2-amino-6-trifluoromethoxybenzothiazole, RP 
54274) Fig. (17) is considered as neuroprotective agent with 
anticonvulsant properties. Its mechanism of action involves 
primary inhibition of VGSC but also reduction of glutamate 
release [32]. 
 
 
Fig. (17). Chemical structure of riluzole. 
 
It inhibited persistent sodium current in dose-dependent 
manner with EC50 of 2 M while tested in rat brain neurons 
[32]. Other studies conducted in bovine adrenal chromaffin 
cells showed blockade of Na+ channels by riluzole in con-
centration-dependent manner with IC50=5.3 μM and binding 
to the veratridine site 2 of channels. In the test using rat brain 
sodium channel -subunits expressed in Xenopus oocytes the 
compounds blocked the close state of the channel with IC50 
ranging from 30 to 90 M, but inhibited the inactivated state 
of Na channels 150–300 times more effectively [66]. Rilu-
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zole in the only drug currently approved for the treatment of 
Amyotrophic Lateral Sclerosis (ALS) [32]. It is also a non-
competitive NMDA antagonist. In a progressive stratial de-
generation the compound was able to reduce motor symp-
toms associated with striatal lesions [67].  
Ranolazine 
Ranolazine ((+)-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-
(2-methoxyphenoxy)propyl]-1-piperazineacetamide) (Fig. 
18), a drug for the treatment of chronic angina [68], was pre-
viously evaluated as modulator of function of different so-
dium channels like NaV1.4, NaV1.5, NaV1.7, NaV1.8, and 
recently also NaV1.1. In the study, human wild-type and mu-
tant NaV1.1 channels expressed heterologously in human 
tsA201 cells were used. The compound was able to block 
persistent current 16-fold more selective in comparison to 
tonic block of peak current and 3.6-fold more selective than 
use-dependent block of peak current. Interestingly, similar 
selectivity was observed for ranolazine in blockage of in-
creased persistent current exhibited by NaV1.1 mutant chan-
nels. Ranalozine proved also ability to cross the blood-brain 
barrier while tested in rats, which together with inhibition of 
persistent current in mutant NaV1.1 channels give rise for 
possible providing a new useful therapeutic strategy for 
SCN1A-associated epilepsy and some migraine syndroms 
[69]. 
 
 
Fig. (18). Chemical structure of ranolazine. 
2. POTASSIUM CHANNELS 
Voltage-gated Potassium Channels 
Voltage-gated potassium channels (VGKCs, KV) belong 
to broad family of potassium channels, including besides 
them Ca2+-activated (KCa, ligand-gated), inward-rectifying 
(KIR), and two-pore (K2P) channels, which all contribute to 
the excitability of neurons, signaling in the nervous system 
as well as ion homeostasis. Potassium ion channels play 
critical role in repolarization of action potentials and regula-
tion of firing frequency [70]. VGKCs were for the first time 
successfully cloned from Drosophila melanogaster cDNAs 
[71]. Tempel et al. [72] isolated mammalian cDNA of KV1.1 
from mouse brain, later research has led to encoding of 
cDNA of other members of KV1 family, and finally to isola-
tion of cDNAs of all currently known potassium channels 
[73]. In 2005 Gutman et al. [74] provided an opinion of In-
ternational Union of Pharmacology concerning classification 
as well as deep review of pharmacology, regulation of ex-
pression, and disease association of voltage-gated potassium 
channels. In the current paper we would like to focus on 
VGKCs as targets in CNS disorders.  
Voltage-gated potassium channels contain four trans-
membrane pore-forming voltage-sensing -subunits. Indi-
vidual -subunit of KV channel consists of six segments (S1-
S6). Four transmembrane S4 segments carry multiple posi-
tive charges and act as main voltage-sensing component, 
which responds to changes of membrane potential resulting 
in conformational alterations in the channel (voltage gating). 
Segments S5 and S6 from each of the four -subunits form a 
pore, which is in fact an ionic conductance pathway. At the 
narrowest part of the pore, S5 and S6 connecting loop form a 
selectivity filter (P). Voltage-sensing segments surround the 
pore. Thus, the structure is similar to described above volt-
age-gated sodium channel. Although most of KV channels 
are homotertamers (four -subunits are the identical), they 
may also form heteroteramers, in which two or more distinct 
types of -subunits occur (e.g. KV7.2/KV7.3). Those hetero-
teramers may possess different properties in comparison to 
homotetramers [70, 73]. Native neuronal potassium channels 
complexes contain both cytoplasmic and transmembrane 
auxiliary -subunits Fig. (19). Several genes that code -
subunits were identified. Their alternative splicing can gen-
erate the number of functionally distinct isoforms. Moreover, 
although called auxiliary, they proved to be able to dramati-
cally alter -subunits expression and localization as well as 
functions by means of changing gating properties of chan-
nels [73].  
3D reconstruction of the KV -subunit suggested that it is 
arranged in two distinct domains: the larger membrane-
embedded and smaller cytoplasmic domain. Both domains 
are connected together by thin linker. The structure of the 
 
Fig. (19). Schematic arrangement of the -and -subunits of KV channel characteristic for KV1 and KV4 subfamily. There are differences in 
position of -subunit. 
A)       B)    
Ion Channels in CNS Disorders Current Medicinal Chemistry, 2013, Vol. 20, No. 10    1251 
membrane-embedded domain is highly homologous among 
all KV families [70]. On the other hand, the cytoplasmic do-
main differs both in structure and function between different 
KV types. The very important part in cytoplasmic domain is 
so called tetramerization domain (T1), which is responsible 
for promoting the tetramerization of potassium channels 
subunits. T1 may be connected with cytoplasmic N-terminal 
fragment of the polypeptide chain, like in KV1- KV4 [75]. On 
the other hand KV7 and KV11 possess a unique tetrameriza-
tion domain in the C-terminal region, which also form the 
binding sites for various ligands (calmodulin, phosphadiyli-
nozytol-4,5-bisphosphate - PIP2, and cyclic nucleotide) that 
can modulate the channel’s function [76-78]. 
Currently KV channels are divided based on the relative 
sequence homology into twelve subfamilies: KV1-KV12. 
KV1-KV4 channels were classified in one group, KV7 in an-
other, KV5, KV6, KV8, KV9 in different ,and KV10-KV12 in 
the last. Among the subfamilies, KV5, KV6, KV8 and KV9 did 
not prove to yield functional expression in forming ion chan-
nels, that is why they are also called “electrically silent” -
subunit-like polypeptides. Undoubtedly they are able to 
modulate the expression and/or gating of channels formed 
from bona fide -subunits which is similar to -subunits 
functions. Names beginning with KCN refer to genes which 
code proteins of different -subunits of potassium channels 
[73]. Early classification provided a division of voltage-
gated potassium channels into three families: Shaker, 
KvLQT and ether-a-go-go. Ether-a-go-go family was further 
divided onto three subfamilies: eag, elk and erg. Those 
names still exist in the literature, they were created before 
providing the current classification and identification of 
broad range of currently known voltage-gated potassium 
channels (Table 4).  
Voltage-gated potassium channels are present in whole 
organism, in different organs like: brain, spinal cord, skeletal 
and smooth muscle, heart, retina, lung, islets, spleen, thymus 
and many more (see Gutman et al. [74]). Expression of dif-
ferent subtypes throughout brain and spinal cord show spe-
cific patterns of subcellular localization, for example KV1 
and KV3 are situated mostly in axons and in some dendrites 
(KV1.1, KV3.1, KV3.2), while KV2 and KV4 in neuronal so-
mata and dendrites [73]. A great majority of known VGKCs 
Table 4. Classification of Voltage Gated Potassium Channels [According to 74] 
Other Name 
Type of Potassium 
Channel 
Human Gene Other Name 
Type of Potassium 
Channel 
Human Gene 
KV1.1 KCNA1 KvLQT KV7.1 KCNQ1 
KV1.2 KCNA2 KQT2 KV7.2 KCNQ2 
KV1.3 KCNA3 - KV7.3 KCNQ3 
KV1.4 KCNA4 - KV7.4 KCNQ4 
KV1.5 KCNA5 - KV7.5 KCNQ5 
KV1.6 KCNA6 KV2.3rc KV8.1 KCNV1 
KV1.7 KCNA7 - KV8.2 KCNV2 
Shaker-related family 
KV1.8 KCNA10 Modifiers KV9.1 KCNS1 
KV2.1 KCNB1  KV9.2 KCNS2 
Shab-related family 
KV2.2 KCNB2  KV9.3 KCNS3 
KV3.1 KCNC1 eag1 KV10.1 KCNH1 
KV3.2 KCNC2 eag2 KV10.2 KCNH5 
KV3.3 KCNC3 erg1 KV11.1 KCNH2 
Shaw-related family 
KV3.4 KCNC4 erg2 KV11.2 KCNH6 
KV4.1 KCND1 erg3 KV11.3 KCNH7 
KV4.2 KCND2 elk1, elk3 KV12.1 KCNH8 Shal-related family 
KV4.3 KCND3 elk2 KV12.2 KCNH3 
Modifier KV5.1 KCNF1 elk1 KV12.3 KCNH4 
KV6.1 KNCG1 
KV6.2 KCNG2 
KV6.3 KCNG3 
Modifiers 
KV6.4 KCNG4 
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are located in CNS but only few of them proved the ability to 
serve as drug targets in disorders like epilepsy (KV7.2-
KV7.5), psychosis (KV7), ataxia type I (KV1.1), multiple scle-
rosis (KV1.3). There is also growing evidence that auto-
antibodies reactive to voltage-gated potassium channels play 
a pathogenic role in a broad spectrum of CNS disorders. 
Raised level of voltage-gated potassium channels antibodies 
(VGKCs-Ab) have been reported in cases of limbic encepha-
litis, while the improvement in neuropsychological function-
ing in some patients correlated with the fall in antibodies. 
Thus, a term autoimmune limbic encephalitis (ALE) was 
introduced, for indistinguishable from other encephalo-
pathies. Limbic encephalitis is commonly associated with 
syndromes like episodic memory impairment, disorientation, 
seizures, hallucinations, and sleep disturbance [79]. Raised 
level of VGKCs-Ab was also confirmed in patients with long 
standing drug resistant epilepsy [80] and in case of adult-
onset drug refractory seizure disorder [81].  
Epilepsy 
Voltage-gated potassium channels, because of their con-
tribution to excitability of neurons, may serve as drug target 
in epilepsy. K+ currents occurring while opening the chan-
nels take part in reducing membrane excitability, thus 
VGKCs openers are of interest as antiepileptic drugs [82]. 
The especially interesting group of potassium channels while 
considering therapy of epilepsy is KV7 (KNCQ) family or 
sometimes even more specified KV7.2 and/or KV7.3. The 
members of KNCQ family, KV7.1 – KV7.5, are characteristic 
for different localizations in human organism, but only chan-
nels from KV7.2 to KV7.5 were found in brain (Table 5). KV7 
channels in physiological condition are activated by mem-
brane depolarization at subthreshold membrane potentials 
(from about -60 mV) and produce a sustained outward cur-
rent at membrane voltages negative to the firing threshold of 
action potentials, thus act as efficient inhibitors of neuronal 
excitability [83, 84].  
KV7 channels were originally termed “M-channels” as all 
members of those family generated so called M-like currents 
when expressed in oocytes or cell lines. It was proved, that in 
native neurons, M-channels are composed of heteromeric 
KV7.2/KV7.3 subunits or homomeric KV7.2 subunits, proba-
bly with a contribution of KV7.5 [83].  
Activity of KV7 channels may be modulated by means of 
several ligands of G-protein coupled receptors (GPCRs), 
which produce several signaling pathways (hydrolysis of 
PIP2; changes in local Ca
2+ concentration; phosphorylation 
by protein kinases), which finally inhibit activity of potas-
sium channels. Exact mechanism of that modulation is not 
completely understood. It was also proved that M-like cur-
rents are inhibited by activation of muscarinic receptors [84]. 
On the other hand, synthetic activators of KV7 seem to cause 
conformational changes leading to channel opening by direct 
binding to the protein [82]. 
Identification of KCNQ2 and KCNQ3 genes mutations as 
the molecular cause of benign familial neonatal seizures 
(BFNS; an autosomal dominant idiopathic epilepsy syn-
drome of newborns, characterized by unprovoked partial 
seizures typically beginning at the age of around three days), 
supported the position of those channels as drug targets in 
epilepsy. Those mutations are located in C-terminal cyto-
plasmic region, but missense mutations within the trans-
membrane have also been described [85, 86]. More evidence 
were found in animals. Watanabe et al. provided results from 
test in Kcnq2-knockout mice. Homozygotus mutant died 
within first postnatal day, while heterozygotus animals char-
acterized normal behavior and morphology compared with 
wild-type mice. Further studies showed that Kcnq2+/- mice 
had much higher sensitivity to the chemoconvulsant – pen-
tetrazole, [87]. Yang et al. gave evidence that mutation in 
Kcnq2 gene led to the decreased seizure threshold in electric-
induced convulsions. Kncq2 mutation was also proved to be 
characteristic for Szt1 mice, which serve as genetic model of 
epilepsy [88]. Peters et al. showed that suppression of the M-
currents in mice was the cause of spontaneous seizures and 
M-channels were found to be critical determinants of cellular 
and neuronal network excitability [89]. Pharmacological 
effectiveness in epilepsy was proved for KV7 channels acti-
vators (like retigabine described below). On the other hand, 
their blockers produced pro-epileptic side effects like trem-
ors, thus their utility as therapeutics in other diseases is lim-
ited [83].  
Psychosis 
KV7 (KCNQ) channels may represent a potential target 
for the treatment of psychosis, as some of them (KNCQ2 and 
Table 5. Localization of KV7 Family Members in Humans [73, 74, 83] 
Localization Type of Potas-
sium Channel -
subunit CNS Subcellular Other 
Disease In Which Serves As Target 
KV7.1 - - Heart, kidney, rectum, lung, placenta, cochlea Arhytmias 
KV7.2 Brain, ganglia Axons Lung, testis, heart, eye, small intestine, breast Epilepsy 
KV7.3 Brain, ganglia 
Axons, neuronal 
somata, dendrites 
Testis, retina, colon, eye Epilepsy 
KV7.4 Brain  Cochlea, vestibular hair cells, placenta 
Epilepsy 
Psychosis 
KV7.5 Brain, ganglia 
Neuronal somata, 
dendrites 
Skeletal muscle Epilepsy 
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KNCQ4) are expressed postsynaptically in dopaminergic 
neurons of mesolimbic and nigrostriatal pathways (e.g. in the 
ventral tegmental area). Opening of those channels is ex-
pected to decrease neuronal excitability, which can affect 
psychotic symptoms believed to be associated with an in-
creased excitability of dopaminergic cells in the mesen-
cephalon. The evidence that dopamine D2 receptors are 
functionally coupled with KV7 channels in dopamine neuron 
was proved by means of co-expressed channels and receptors 
in Xenopus oocytes and human neuroblastoma cells [90]. In 
other studies, the firing of dopaminergic neurons recorded in 
rat mesencephalic slices was significantly inhibited in a con-
centration-dependent manner by retigabine and that com-
pound completely blocked the excitatory effect of dopamine 
D2 autoreceptor antagonists, suggesting that the modulation 
of dopaminergic activity by D2 autoreceptors would involve 
the activation of KCNQ2 and/or KCNQ4 channels [91]. 
More evidence came from in vivo electrophysiological stud-
ies conducted in anesthetized rats, in which KV7 channels 
activators (e.g. retigabine) suppressed burst firing activity in 
the ventral tegmental area, whereas XE-991, a selective 
KNCQ blocker, induced opposite effect. In the conditioned 
avoidance response paradigm one of in vivo rat models pre-
dictive for antipsychotic activity, retigabine was found to 
inhibit avoidance responses, moreover that effect was 
blocked by coadministration of XE-991. Furthermore, in 
phencyclidine (PCP)-sensitized rats, considered as a model 
for schizophrenia, retigabine was found to significantly in-
hibit the hyperlocomotor response to a phencyclidine chal-
lenge [92]. 
Above findings combined with immunocytochemistry 
test, which revealed that KV7.4 is the major KV7 channel 
type expressed in dopaminergic neurons [91] support for the 
hypothesis that those channels may serve as drug target in 
psychosis and that their activators could become a new class 
of antipsychotic drugs. 
Episodic Ataxia 
Episodic ataxia type I (EA1) belongs to paroxysmal 
movement disorders. It is an autosomal-dominant disorder, 
characterized by intermittent cerebellar dysfunction with 
otherwise essentially normal brain function [93]. It was iden-
tified as a channelopathy connected with mutations in KV1.1 
gene (KCNA1 in chromosome 12p13) [94]. A common 
clinical features associated with EA1 are: from CNS - occur-
rence of seizures, from peripheral nerves – neuromyotonia, 
but no connection with headache during acute episode was 
proved [95]. On the other hand, episodic ataxia type II is 
caused most often by the mutation in calcium channel gene 
CACNA1A, but potassium channel blocker – 4-amino pyri-
dine, is one of the efficient treatment option [96]. Currently 
no VGKCs ligand is used in the therapy of EA1. 
Multiple Sclerosis 
Multiple sclerosis (MS) is a disease of central nervous 
system, of which myelin damage is one of the pathological 
issues. There are various theories about the etiology of MS 
including immunologic, environmental, genetic, and infec-
tious factors [97]. Myelin damage has been shown to cause 
abnormal K+ currents, thus potassium channels are believed 
to play an important role in multiple sclerosis, as they are 
responsible for conductance failure in that condition. Potas-
sium channels blockade reduced this ionic leakage and im-
proved conductance. Moreover, some VGKCs blockers were 
successfully used in many in vitro studies and animal models 
of neurodegenerative disorders as well as in clinical trials. 
Voltage-gated sodium channels, and especially KV1.3, were 
connected with several autoimmune diseases including MS. 
KV1.3 are expressed among others in immune system cells 
and organs like thymus, spleen, macrophages, lymphocytes. 
Blockage of those receptors localized in T-lymphocytes 
proved to be an effective approach in managing autoimmune 
disorders [98].  
Voltage-gated Potassium Channels Modulators 
Voltage-gated potassium channels constitute a wide and 
hererogenous group thus no common binding pattern could 
not be determined. Modulators of different type potassium 
channels were recently reviewed by Wulff and Zhorov [99]. 
Here we would like to focus on selected VGKCs ligands and 
their utility in CNS disorders.  
Retigabine (RTG; Ezogabine) 
Retigabine (N-[2-amino-4-(4-fluorobenzylamino)-phe 
nyl]carbamic acid ethyl ester) Fig. (20) represents a unique 
mechanism of action among AEDs which is enhancing of the 
activity of KV7 channels in central nervous system resulting 
in reduction of neuronal excitability. The other mechanism 
constitutes enhancing of -aminobutyric acid transmission 
but only at supra-therapeutic concentration (while tested in 
vitro) [100]. The compound showed broad anticonvulsant 
activity in several animal seizure models: MES, scMet, 6-Hz 
test, hippocampal-kindled rats, amygdala-kindled rats ,and 
many more, including some genetic animal models of epi-
lepsy [100]. Moreover, it had antipsychotic effect in an ani-
mal model of schizophrenia and mania [92]. It also showed 
activity in rat models of neuropathic pain [37]. 
 
 
Fig. (20). Chemical structure of retigabine. 
 
Retigabine is thought to bind selectively to KV7.2 – 
KV7.5 channels, shifting the current–voltage curve to the left, 
which results that the channels open at more hyperpolarized 
membrane potentials [101]. The lack of RTG effect on KV7.1 
may be due to inefficient binding, which, however, has not 
been proved [82]. It increased the rate of channels activation 
while tested in Xenopus oocytes expressing KCNQ2 [102]. 
Retigabine, at concentration 0.1 – 10 M, affected CHO 
cells expressing KV7.2/KV7.3 heteromeric channel (CHO-
KNCQ2/Q3) resulting in increasing M-like potassium cur-
rents and hyperpolarization of the cell membrane. Moreover, 
it shifted the voltage dependence of channel activation with 
an EC50 value of 1.6±0.3 M [103]. The compound also sig-
nificantly influenced properties of Xenopus oocytes mem-
brane expressing recombinant human KV7.2/KV7.3, as well 
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as channel itself. At the concentration of 10 M RTG shifted 
both the activation threshold and voltage for half-activation 
by approximately 20 mV in the hyperpolarizing direction. It 
also affected kinetics of the channels, causing increased rate 
of activation and slowing deactivation. Membrane potential 
recordings showed that the compound caused a concentra-
tion-dependent hyperpolarization of the oocyte (IC50 of 5.2 
M) [102].  
The prove that retigabine acts through activation of KV7 
channels came also from in vivo animal studies. In two of 
them anticonvulsant efficacy was reduced by the selective 
KV7 blocker, XE-991.That happened in MES test in mice 
and in the rapid kindling model in rats [100]. Other test were 
performed in the Szt1 mouse model, in which functionality 
of the KV7.2 channel is impaired, because of C-terminal de-
letion in the Kcnq2 gene. Research showed that anticonvul-
sant potential of retigabine was then reduced [104]. It is 
worth to mention, that neuroprotective effect of RTG proved 
in some in vitro studies was not mediated by KV7.2 [100].  
Systematic mutagenesis studies identified segment S5 as 
a binding site for retigabine, and more detailed a crucial tryp-
tofan residue, which is specific for KV7.2 – KV7.5, while in 
KV7.1 there is leucine in corresponding position. Additional 
residues have also been found as affected by retigabine, like 
glycine residue in S6 [82].  
Retigabine has recently been approved as adjunctive 
therapy in adults with partial-onset seizures [100].  
ICA-27243 
ICA-27243 (N-(6-chloro-pyridin-3-yl)-3,4-difluoro-ben 
zamide) Fig. (21), considered as a second-generation struc-
ture to retigabine, is a selective activator of KV7.2/7.3. It 
showed in in vivo animal tests a broad spectrum of anticon-
vulsant activity including the MES, scPTZ, 6 Hz and kin-
dling models [22]. 
 
 
Fig. (21). Chemical structure of ICA-27243. 
 
ICA-27243 is a potent and selective activator of 
KV7.2/7.3 showing EC50=0.20±0.03 M, determined in 
86RB+-efflux assay conducted on recombinant human chan-
nels expressed in CHO cells. It the same test, EC50 for acti-
vation of KV7.4 was 7.1±0.1 M and for KV7.3/7.5 was not 
able to be determined but estimated at about 10 M. ICA-
27243 shifted the voltage-dependent activation of KV7.2/7.3 
to more hyperpolarized potentials in concentration-depen 
dent manner. The halfmaximal shift in the midpoint of the 
activation curve ( V1/2) was observed at 4.8±1.6 M. The 
compound had no effect on GABAA-activated chloride 
channels, NaV1.2, or CaV channels. 
Preclinical tests with ICA-27243 provided the evidence 
that KV7.2/7.3 activation alone is sufficient for broad-
spectrum anticonvulsant activity in rodents. The finding that 
ICA-27243 can discriminate among different KV7 subtypes 
suggests that it may interact at a novel binding site on KV7.2 
and/or KV7.3 channels that is not present in other KV7 chan-
nels. The binding site has anyway not yet been identified 
[105, 106]. 
4-Aminopyridine 
4-Aminopyridine (4-AP, fampridine) Fig. (22) inhibits in 
dose-dependent manner fast voltage-gated potassium chan-
nels including KV1.1, KV1.2, KV1.4- KV1.7, KV3.1- KV3.3, 
KV4.1. It also increases Ca
2+ influx at presynaptic endings.  
 
 
Fig. (22). Chemical structure of 4-aminopyridine. 
 
In in vitro experiments it proved to selectively inhibit so-
called A-potassium current, which is characteristic for some 
members of KV. The sensitivity of different channels varied 
from micromolar to millimolar concentrations of 4-AP and 
in particular channel the sensitivity depended on its state 
(open or closed). It was proved that the compound more 
readily affected open than closed channels and did so from 
the cytoplasmic site and is not transferred with the pore 
[107]. KDs while inhibiting KV2.1 and KV3.1 expressed in 
Xenopus oocytes were 17 and 0.08 nM, respectively and the 
mechanism of action remained similar [108]. It also proved 
activity in several in vitro models of neuronal degeneration, 
significantly improving function of neurons [107]. 
4-Aminopyridine proved efficiency in few clinical trials 
in patients with multiple sclerosis [107]. The compound was 
also efficient in episodic ataxia type II, probably due to in-
creasing the inhibitory influence of the Purkinje cells [96]. It 
was approved in January 2010 for patients with MS to im-
prove their walking [97]. 
3. CALCIUM CHANNELS 
Calcium channels have been well known drug targets and 
still they are subject of intensive research. Lately, they have 
been reveiewed by Belardetti [109]. Voltage-gated calcium 
channels are present in membranes of excitable cells. They 
are opened during depolarization and this gives rise to an 
influx of Ca2+. Increase in concentration of this ions stimu-
lates an ongoing depolarization by opening other voltage-
gated ion channels. In addition they initiate a release of neu-
rotransmitters [110]. Moreover, calcium ions act as a second 
messenger and activate enzymatic processes [111].  
Calcium channels consist of two families: HVA (High 
Voltage-Activated) and LVA (Low Voltage-Activated). 
HVA family comprises L-, N-, P-, Q-, and R-type channels. 
They are heterotrimers of subunits , , and 2- . Subunit  
forms a pore with ancillary subunit . Subunit 2-  forms a 
functional pore by linking with subunit . LVA family con-
sists of T-type channels which are monomers and are com-
posed only of subunit . LVA and HVA differ in function 
and electrophysiological activity. LVA requires a small 
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amount of depolarization, close to resting membrane poten-
tial in order to be opened. In contrast to HVA, they are acti-
vated and inactivated very quickly. LVA also display low 
conductance and better resistance to blockers [112]. 
 
 
Fig. (23). Schematic structure of calcium channels. 
 
A role of Cav1 is to respond to depolarization by induc-
ing intracellular processes. They occur in various sorts of 
tissues and are responsible for many intracellular activities. 
In skeletal, smooth muscles and myocytes an influx of Ca2+ 
leads to contraction. In neurons, Cav1 modulate genes’ tran-
scription. Majority of them occur in a cell body and proximal 
part of dendrites to ease access for Ca2+ to nucleus. In addi-
tion they initiate release of neurotransmitters. This subtype 
of calcium channels have been a cardiovascular targets, 
however, due to their presence in neurons, they play some 
role in low-potassium triggered paralysis (CaV1.1), autism, 
depression, bipolar disorder, or schizophrenia (CaV1.2), and 
deafness (CaV1.3) [109].  
Cav2 occur in presynaptic nerve terminals in most CNS 
synapses. Their main role is to mediate release of neuro-
transmitters to synapses. Depolarization results in an opening 
of Cav2 and an influx of Ca
2+. Ions bind with proteins called 
synaptogamins, placed on a surface of synaptic vesicles 
which contain neurotransmitters. Then synaptic vesicles fuse 
with presynaptic membranes and neurotransmitter is re-
leased. The release of neurotransmitter occurs by exocytosis. 
After that the neurotransmitter binds to a postynaptic recep-
tor, mediating an excitation [113]. Mutations of Cav2 chan-
nels can influence its functions. Changes in P/Q-type chan-
nels lead to appearance of absence epilepsy. By substitution 
particular amino acids, an activity of these channels are re-
duced. In consequence there is a diminished ability to excite 
neurons [114]. 
Cav3 mainly occur in neurons and the heart. In CNS, they 
are responsible for a process of dreaming and their mutation 
leads to appearance of absence epilepsy [114]. These chan-
nels are capable of activation when a membrane potential is 
close to the resting membrane potential -60mV. A small de-
polarization triggers an opening of channels and an influx of 
Ca2+. In consequence the depolarization continues by activa-
tion Na+ and Ca2+ channels. At the time of repolarization, 
these channels deactivate slowly (become closed) which 
allows to flow of a larger amount of Ca2+. In the end of dis-
charge hyperpolarization appears, bringing about closure of 
inactivated calcium channels [112]. It is essential as depo-
larization is possible only when calcium channels are closed 
(deactivated) [115].  
A feature of Cav3 channels is that they contribute to vari-
ous models of excitability in neurons. There are 3 models: 
1) Tonic firing Fig. (24) 
It is a single burst of action potential. If a cell is more depo-
larized than -60mV for 50 – 100 msec, calcium channels are 
inactivated, and the cell responds to an excitatory input in 
tonic mode [115, 116]. 
 
 
Fig. (24). Tonic firing of neurons. 
 
2) Low-threshold burst firing Fig. (25) 
This type of firing occurs when a membrane is hyperpolar-
ized below -65mV for >50 - 100 msec. The hyperpolariza-
tion is essential in order to make calcium channels shift from 
being inactivated to being closed. During depolarization cal-
cium channels are activated and elicit a low-threshold Ca2+ 
spike (LTS) with a burst of 1–10 action potentials. Because 
of influx of calcium ions a membrane potential diminish to -
40mV. Consequently it leads to an activation of voltage-
gated sodium channels [115, 116].  
 
 
Fig. (25). Low-threshold burst firing of neurons. 
 
3) Slow oscillations (<1Hz) 
T-type calcium channels produce a large window current in 
the membrane potential’s range of -60 to -40 mV and are 
always open and do not inactivate. It is possible because 
there is an overlap between activation, inactivation, deactiva-
tion within this range of membrane potential. It enables a 
sustained influx of calcium ions and plays an important role 
in the process of dreaming [117]. 
Drug Dependency 
L-type calcium channels play a necessary role in sensiti-
zation to psychostimulants, seen in an animal model of in-
centive/motivational aspect of cocaine and amphetamine 
dependency. Their block in the nucleus accumbens prevents 
cocaine reinstatement and self-administration in rats [120]. It 
would be interesting if clinical evidence was provided for 
use of a CaV1 channel antagonist in treatment of drug de-
pendency. 
Parkinson’s Disease 
There is both molecular and clinical evidence that CaV1.3 
activity contributes to cell death within substantia nigra, 
leading to deficiency of dopaminergic neurons in this area, 
which is a known cause for Parkinson’s Disease. From the 
clinical point of view, cardiovascular patients treated by L-
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type calcium blockers penetrating blood-brain barrier sig-
nificantly reduced risk of PD in patients [109]. 
It has been noticed that mutation in CaV2.1 gene causes 
familial hemiplegic migraine [121]. Contrary to this fact, 
CaV2.1 mice are severely ataxic and display absence sei-
zures, followed by death at the age of 4 weeks [122]. Both 
these facts discourage from targetting CaV2.1 in drug discov-
ery process. 
Pain 
N-type (CaV2.2) calcium channels blockers have been a 
prime target for analgesics as they are expressed in the dorsal 
horn of the spinal cord. They transmit pain signals from af-
ferent neurons to second order neurons projecting to higher 
CNS centers. They also are a target for descending activation 
of noradrenergic pathways by norepinephrine and for inhibi-
tion by opioid pathways [123]. The first analgesic drugs to 
be registered as antagonists of CaV2.2 was ziconotide, a pep-
tide derivative of -conotoxin-MVIIA. Its toxicity, which 
probably resulted from small selectivity to the targets, nar-
rowed the use of these compounds. Intrathecal administra-
tion was also a considerable disadvantage so far [109]. How-
ever, there are some efforts in drug discovery for analgesics 
acting by antagonism of CaV2.2 (see below).  
Absence Epilepsy 
Absence epilepsy is associated with generalized epileptic 
seizures which concerns 10% of population suffering from 
epilepsy. It is characterized by loss or impaired conscious-
ness, which lasts up to 30 seconds. During an attack of epi-
lepsy the patient displays absent impression on his face and 
does not respond. It is accompanied by quivering of the eye-
lids, turning pale and relaxation of facial muscles. Patient 
experiences amnesia and is not aware of having seizures.  
The cause of absence epilepsy is abnormal hyperexcita-
bility of neurons in a thalamus-cortex circuitry. In EEG re-
cords occur oscillation consisted of multiple spike-waves and 
slow-waves at more than 2.5 Hz, predominantly 3–6 Hz. The 
thalamus-cortex circuitry comprises:  
• Thalamic relay cells of the ventroposterolateral and ven-
troposteromedial thalamic region 
• Pyramidal neurons in the cortex (layers III-VI) 
• Reticular thalamic nucleus (RTN) [124] 
CaV2 and CaV3 types of calcium channels are present in 
thalamic relay cells and RTN Fig. (26). Thus in both struc-
tures two models of neurons’ excitability are possible – tonic 
and burst firing. The tonic firing mode is characteristic of 
stages of high vigilance. The burst firing is characteristic of 
dreaming process and some pathological states like absence 
epilepsy [124]. 
In a properly working circuitry, thalamic relay cells exert 
glutamatergic projections on pyramidal neurons in layers III 
and IV. These pyramidal neurons project to pyramidal neu-
rons in layer V and VI of the cortex. Then they re-innervate 
thalamic relay cells with glutamate as a neurotransmitter. 
Both thalamic relay cells and cortex are linked to reticular 
thalamic nucleus by glutamatergic neurons. RTN comprises 
only GABAergic interneurons. It is linked with thalamus and 
projects inhibitory neurotransmitter. GABA leads to hyper-
polarization of memebrane of thalamic relay cells and this 
allows calcium channels to shift from inactivated state to 
deactivated state. Consequently calcium channels can be 
opened and the burst firing occurs [124]. In EEG record 
there are characteristic oscillations. Spikes represent an ex-
citability of neurons during glutamatergic projections. Waves 
appear when RTN projects inhibitory neurotransmitter [125]. 
During absence epilepsy seizures, spike-wave discharges 
are observed in the cortex [126]. These discharges lead to an 
excitability of reticular thalamic nucleus. RTN projects 
GABA to thalamic relay cells and causes sustained inhibition 
of thalamic relay cells. This enables calcium channels to 
become deactivated enough. As a result, burst firing does not 
 
Fig. (26). Thalamus-cortex circuitry. 
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occur. It is claimed that inhibition of thalamus causes loss of 
consciousness during absence seizures [127].  
Knock-out of CaV2.1 calcium channels gives rise not 
only to seizures, but also to ataxia, while gain of function 
mutations may be related with familial migraine [109].  
Nifedipine 
Nifedipine, amlodipine, and nimodipine Fig. (27) are di-
hydropyridine derivatives. They have been developed as 
cardiovascular drugs, blocking L-type (CaV1) calcium chan-
nels. Amlodipine blocks CaV1.2 with IC50=100 nM and 
CaV2.1 with IC50=10 M. Many drugs from the group of 
dihydropyridines crossing blood-brain barrier, including 
nifedipine and nimodipine (and excluding amlodipine), 
proved efficacy in preventing Parkinson’s disease in over 
25% of patients [128]. However, in an animal study, nifedip-
ine lowered anticonvulsant activity of topiramate in mice (it 
doubled its ED50). The authors suggest some pharmacody-
namic interaction, e.g. L-type calcium channel binding of 
topiramate, rather than pharmacokinetic or any other interac-
tion between nifedipine and topiramate [129]. These facts 
concerning derivatives of dihydropyridine are premises for 
drug discovery of more selective derivatives vs. CaV1 chan-
nels subtypes. 
Pregabalin 
Pregabalin (CI-1008, (S)-3-aminomethyl-5-methylhexa 
noic acid) Fig. (28), is a derivative of GABA. It binds to the 
2  subunit of the CaV2 calcium channels. Moreover, it in-
creases GABA concentration in neuronal tissues and en-
hances activity of glutamate decarboxylase. It is a well-
known antiepileptic drug, exhibiting both anticonvulsant and 
analgesic activity in central and peripheral neuropathic pain. 
[130-132].  
Gabapentin 
Gabapentin (1-(aminomethyl)cyclohexaneacetic acid)    
Fig. (29) is a GABA derivative. It exhibits binding to 2  
subunit, causing inhibition of CaV2 calcium channels. The 
additional mechanism is related with the above, i.e. it inhib-
its release of glutamate, relieving neuronal hyperexcitability. 
It is a well known antiepileptic drug with proved preclinical 
and clinical efficacy in epilepsy and pain [133, 134]. 
Ziconotide 
Ziconotide, SNX-111, this antagonist of CaV2.2 is regis-
tered for treatment of chronic pain, although it is adminis-
tered intrathecally [118]. It is a synthetic analog of -
conotoxin-MVIIA.  
Pyrazolylpiperidine Derivative 
This compound (Fig. (30) has been synthesized for 
screening vs. CaV2.2 channel, taking into account the need 
for an orally administered and metabolically stable anticon-
vulsant with a similar mechanism of action to ziconotide. It 
is active in a chronic constriction injury model for neuro-
pathic pain (rats, i.p.) at 30 mg/kg b.w. (cold hypersensitiv-
ity) and in carrageenan-induced inflammatory pain (thermal 
hypersensitivity) [119]. 
Ethosuximide and Mesuximide 
Ethosuximide (3-ethyl-3-methylpyrrolidine-2,5-dione) 
and mesuximide (1,3-dimethyl-3-phenylpyrrolidine-2,5-
dione)    Fig. (31) are well established anticonvulsants, active 
in absence epilepsy. They show affinities towards CaV3 re-
ceptors. They are inactive in grand mal seizure models in 
rodents (e.g. MES), and active in petit mal epilepsy model – 
ethosuximide in scMET test with ED50=167 mg/kg b.w. 
(rats, p.o.) [56]. 
4. P2X RECEPTORS 
Extracellular adenosine 5’-triphosphate (ATP) is an im-
portant excitatory transmitter both in the peripheral and cen-
tral nervous system [135]. P2X receptors are a distinct fam-
ily of ligand-gated membrane ion channels activated by ex-
 
Fig. (27). Chemical structures of nifedipine, amlodipine, and nimodipine. 
 
 
 
Fig. (28). Chemical structure of pregabalin. 
 
   Fig. (29). Chemical structure of gabapentin. 
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tracellular ATP. Human P2X receptors are a family of seven 
isoforms designated P2X1 to P2X7. The isoforms share 26–
54% sequence identity and each subunit is between 379 and 
595 amino acids in length [136-138]. P2X1, P2X2, P2X3, 
P2X4, P2X5, and P2X7 isoforms form functional ho-
momeric receptors, however heteromeric assemblies such as 
P2X2/3 and P2X1/5 channels are also possible [139, 140]. 
P2X7 receptors are unique among the P2X receptor family 
because they fail to form heteromeric forms and are activated 
by high ATP concentrations (>100 M) [141].  
P2X receptors (Fig. (32) are organized as trimers [142] with 
the subunits arranged in a “head-to-tail” order [143]. All 
have two transmembrane domains (TM1 and TM2), an ex-
tracellular ligand binding loop that contains ten conserved 
cysteine residues that form disulphide bonds and intracellular 
amino and carboxy termini [139, 144]. Both TM1 and TM2 
are thought to line an integral ion pore [145]. Thus, the re-
sulting channel is composed of six transmembrane domains, 
two from each of three subunits, the structure that is unique 
in the ion channel literature.  
 
 
Fig. (32). Schematic structure of P2X receptor. 
 
The primary agonist of all P2X receptors is ATP and at 
least 3 molecules of ATP are bound to the extracellular por-
tions of open P2X channels [143]. P2X receptors undergo 
conformational changes leading to the opening of a cationic 
pore within milliseconds of binding ATP [146]. P2X recep-
tors display significant calcium permeability. Moreover, they 
show sodium and potassium permeability [136] and some of 
them are also permeable to chloride [147]. Aside from ATP, 
most P2X receptors are also activated by diadenosine poly-
phosphates or related dinucleotides and some nucleoside 
triphosphates [140, 148].  
P2X receptors are widely distributed in cell types of 
nearly every origin, including neuronal, epithelial, immune 
and muscular. They are involved in actions such as synaptic 
transmission in the peripheral and central nervous systems, 
contraction of smooth muscle, platelet aggregation, macro-
phage activation, cell death and immunomodulation [149, 
150]. 
P2X receptors are widely expressed on central and pe-
ripheral neurons - with P2X2, P2X3, P2X4 and P2X7 being 
the most abundant in the nervous system [151]. P2X recep-
tors have been explored as therapeutic targets, e.g., for 
chronic inflammatory diseases and pain. In particular, P2X3 
and P2X7 receptor antagonists have been developed and 
exhibited antinociceptive or antiinflammatory activity in 
animal models of these diseases [152].  
Apart from neuropathic pain conditions it has also been 
reported that the activation of P2X receptors may be in-
volved in the process of excitotoxic neuronal injury caused 
by stroke [153]. It was proved that following ischemia espe-
cially P2X7 receptors are upregulated on neurons and glial 
cells in rat cerebral cortex [154]. The evidence from prior 
studies, however, showed that the deletion of P2X7 receptors 
(knock-out mice) and/or treatment with KN62, the antagonist 
of P2X7 receptors had minimal effect on ischemic cell death 
[155]. Another study showed that P2X receptors are involved 
in the mechanisms sustaining cell death evoked by metabo-
lism impairment [156]. Additionally, both P2X4 and P2X7 
receptors expressed on microglia might be involved in corti-
cal damage produced by oxygen and/or glucose deprivation 
[157]. Several earlier studies have confirmed the idea as P2 
receptors antagonists were able to abolish the cell death fate 
of primary neurons exposed to excessive glutamate [158], to 
hypoglycemia or chemical hypoxia [159, 160] and to serum/ 
potassium deprivation [161].  
P2X7-mediated signaling is also implicated in neurode-
generative processes observed in CNS diseases, such as 
Parkinson’s and Alzheimer’s diseases and multiple sclerosis 
[162-166]. In case of Parkinson’s disease the release of ATP 
from disrupted cells might cause cell death in neighbouring 
cells expressing P2X7 receptors, consequently necrotic vol-
ume is increased [167]. Moreover, P2X7 receptors are spe-
cifically upregulated in the brain of patients with Alz-
 
Fig. (30). Chemical structure of 1-(2-methoxyphenyl)-3-[4-(1-
methylsulfonyl)piperidinyl]-5-(4-chlorophenyl)pyrazol.  
 
   Fig. (31). Chemical structures of ethosuximide and mesuximide.  
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heimer’s disease (AD) and in animal models of the disease 
[168].  
In two different transgenic models of Huntington’s dis-
ease changes in P2X receptor-mediated neurotransmission in 
cortico-striatal projections have been identified. In addition, 
it was shown that P2X receptor antagonists might have po-
tential as neuroleptic agents as microinjection of ATP ana-
logues into the prepiriform cortex was able to induce gener-
alized motor seizures [169]. Purinergic mechanisms and spe-
cific P2X receptor subtypes have also been involved in the 
pathogenesis of clinical conditions such as amyotrophic lat-
eral sclerosis [170] and epilepsy [171, 172]. 
Suramin 
Suramin (Fig. (33) the best known antagonist of P2X re-
ceptors [173] was assessed for its neuroprotective potential 
in a model of experimental stroke in rats. In the study focal 
brain ischemia was induced by unilateral occlusion and tran-
section of the middle cerebral artery (MCAT) and bilateral 
occlusion of the common carotid arteries (CCA). It was 
shown that suramin at a dose of 100 mg/kg significantly de-
creased both infarct and edema volume. Thus, the compound 
is an effective pretreatment neuroprotective agent [153]. 
 
Fig. (33). Chemical structure of suramin. 
 
CE-224535 
Pfizer’s compound CE-224535 (Fig. (34), a P2X7 recep-
tor antagonist was recently evaluated in the clinic for the 
treatment of rheumatoid arthritis [174]. The compound is 
presently studied for the treatment of other conditions, such 
as pain and Alzheimer´ s disease [175].  
 
 
Fig. (34). Chemical structure of CE-224535. 
5. NMDA RECEPTORS 
N-methyl-D-aspartate (NMDA) receptors (Fig. (35) are a 
subtype of ionotropic glutamate receptors widely distributed 
in CNS. NMDA receptors play a crucial role in synaptic 
transmission, neural plasticity and neurodegeneration [176, 
177], thus may serve as potential CNS therapeutic targets 
[178].  
 
Fig. (35). Schematic structure of NMDA receptor. 
 
NMDA receptors are hetero-oligomeric ligand-gated 
cation channels comprising four NMDA subtypes: NR1, 
NR2, and NR3 [179]. The subtypes include the ubiquitously 
expressed NR1 subunit; a family of four distinct NR2 
subunits (A, B, C, and D); and more rarely two NR3 subunits 
(NR3A and NR3B) [180, 181]. Most NMDA receptors are 
believed to assemble as tetramers, associating two NR1 and 
two NR2 subunits in a ‘dimer of dimers’ quaternary architec-
ture [181-183]. The subunits differ in their permeation and 
block by divalent ions and sensitivity to various endogenous 
and exogenous ligands. It was discovered that NR1 and 
NR2A subunits are the most common and NR2D are the 
rarest. More heterogeneous receptors exist in CNS, compris-
ing multiple types of NR1 and/or NR2 subunit in one recep-
tor complex. Thus, NMDA receptors including NR1/NR2B/ 
NR2A and NR1/NR2B/NR2D can be distinguished in many 
areas of the CNS [184, 185].  
NMDA receptors’ intrinsic ion channel is permeable to 
monovalent cations such as sodium and potassium, and biva-
lent ones including calcium. In order to open the channel 
pore by NMDA receptors the simultaneous binding of glu-
tamate (neurotransmitter role) and the co-agonist – glycine 
(or D-serine, modulators) is needed. The glutamate binding 
site is situated on the NR2 subunit and the glycine binding 
site is situated on the NR1 subunit. NMDA receptor activa-
tion takes place after presynaptic glutamate release and with 
appropriate glycine concentration in the synaptic cleft [177, 
178, 182].  
In general, NMDA receptors are found in many but not 
all cerebral cortex neurons and some cortical astrocytes [178, 
186] and play major roles in both physiological and patho-
logical states of the CNS. Inappropriate activation of NMDA 
receptors has been stated in the etiology of various disorders.  
Stroke 
The first clinical indication considered for NMDA recep-
tor antagonists was stroke. In such ischemic or hypoxic con-
ditions the increased amount of glutamate is released into the 
synaptic clefts, thus the overstimulation of the NMDA recep-
tor is observed [187]. It was proved that the blockade of 
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NMDA receptors resulted in neuroprotective effect in animal 
models of stroke [188]. Also in traumatic brain injury (TBI) 
glutamate is released in large quantities into the extracellular 
fluid by neurons and glial cells. This was confirmed in both 
animal models and human studies [189, 190]. Thus, the ap-
plication of NMDA antagonists might be of therapeutic 
benefit. 
NMDA receptors via calcium fluxes are able to down-
regulate the stream signaling pathways leading to short-term 
and long-term neuronal changes [191]. Thus, alternation in 
these receptors causes deficits in learning and memory [192]. 
Schizophrenia 
Additionally, both genetic and pharmacological studies 
showed that glutamatergic dysfunction, particularly with 
involvement of NMDA receptors plays a vital role in the 
pathophysiology of schizophrenia [193, 194]. It was proved 
that mRNA encoding the NR2B subunit was increased in 
hippocampal and cortical regions in schizophrenia [195, 
196]. Arias et al. [197] suggested that hyperphosphorylation 
of NR2B-containing receptors in vivo may cause increase of 
sensitivity to the endogenous transmitter, and induction of 
neuronal hyperexcitability and epilepsy. 
Parkinson’s Disease 
In the pathophysiology of Parkinson’s disease (PD) over-
reactivity of the glutamatergic pathway may be stated. Thus, 
the manipulation of the glutamatergic system may show anti-
parkinsonian effects [198]. Various studies indicated that the 
NR2B subunit is a important molecular component in the 
etiology of PD and therefore should be considered as a po-
tential therapeutic target for the treatment of the disease 
[199-203]. 
Huntington’s Disease 
Another severe disease related with NMDA receptors is 
Huntington’s disease (HD). It was confirmed that NR2B 
subtype NMDA receptors activation triggers the selective 
degeneration of the medium spinal striatal neurons in HD 
[204]. Mutant huntingtin may increase the number of func-
tional NR1/NR2B-type receptors at the cell surface [205]. 
Moreover, the expression of polyglutamine-expanded hunt-
ingtin results in NMDA receptors sensitization and promotes 
neuronal apoptosis triggered by glutamate [206].  
Gavestinel 
Gavestinel (Fig. (36) a selective antagonist at the glycine 
site of the NMDA receptor and one of the indole derivatives 
was evaluated in various animal models of stroke. In the 
middle cerebral artery occlusion (MCAO) model of focal 
ischemia in rats administration of the compound (3 mg/kg 
i.v.) up to 6 h from occlusion resulted in a significant reduc-
tion of the infarct volume measured histologically 24 h later 
[207]. Moreover, gavestinel was characterized in terms of in 
vivo potency by inhibition of convulsions induced by N-
methyl-D-aspartate in mice. The compound inhibited con-
vulsions induced by NMDA when administered by both i.v. 
and p.o. routes (ED50= 0.06 and 6 mg/kg, respectively) 
[187]. Also magnetic resonance imaging confirmed the po-
tential neuroprotective activity of gavestinel when adminis-
tered either before or up to 6 h after ischemia [208]. Gav-
estinel was well tolerated in early human studies and showed 
no apparent significant CNS or hemodynamic effects [209, 
210]. In a randomised, double-blind, placebo-controlled trial 
to test whether gavestinel could improve functional outcome 
after acute stroke in human beings the treatment with the 
compound within 6 h of acute ischemic stroke did not im-
prove the outcome [211]. Additionally, in clinical trials of 
this compound in patients with intracerebral hemorrhage 
gavestinel was not of substantial benefit or harm to patients 
[212].  
 
Fig. (36). Chemical structure of gavestinel. 
Selfotel 
The competitive glutamate antagonist selfotel (CGS 
19755) (Fig. (37) in preclinical animal tests produced anti-
convulsant, anxiolytic and anti-ischemic effects [213]. The 
compound reduced neuronal damage in animal models of 
stroke [214-216]. In the rat model of global cerebral ische-
mia selfotel treatment (dose ranged from 10 to 30 mg/kg 
intraperitoneally) resulted in neuroprotection that was ob-
served when administration was not delayed more than 30 
minutes after the onset of ischemia [215]. The neuroprotec-
tive effect of selfotel was also confirmed in rats with oc-
cluded left middle cerebral and common carotid arteries. 
Intravenous infusion of selfotel (10 mg/kg) reduced infarct 
volume [214]. The compound was also effective in a rabbit 
model of reversible CNS ischemia [216]. Grotta et al. [215] 
evaluated the safety and tolerability of selfotel in patients 
with acute ischemic stroke. The study showed that although 
adverse effects are related with the treatment in a dose-
dependent fashion, a single intravenous dose of 1.5 mg/kg is 
safe and tolerable with adverse experiences that are control-
lable. In Phase III efficacy trials conducted in patients with 
severe traumatic brain injury the compound (four doses of 5 
mg/kg each, 24 h apart) failed to demonstrate a satisfactory 
risk/benefit ratio. One explanation is that the compound 
which is competitive with glutamate at the receptor may not 
influence events at the receptor site [217]. 
 
Fig. (37). Chemical structure of selfotel. 
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Aptiganel 
Aptiganel (Fig. 38) acts as a noncompetitive NMDA an-
tagonist [218]. In a rat model of human ischemic stroke, ap-
tiganel hydrochloride administered intravenously was able to 
reduce (by 40-70%) the volume of brain damage and the 
accompanying neurological dysfunction. Moreover, in a rat 
model of temporary focal ischemia the compound was able 
to protect both cerebral gray matter and white matter from 
ischemic injury [219]. The study on controlled cortical im-
pact injury of the left temporoparietal cortex in rats demon-
strated that the compound decreased contusion volume and 
hemispheric swelling as well as water content [220]. Neuro-
protective activity of aptiganel HCl was also confirmed in 
controlled cortical impact injury (CCII) in rats. Compound’s 
administration was associated with decrease contusion vol-
ume, less hemispheric swelling, a lower intracranial pressure 
and increased cerebral perfusion pressure [221]. 
 
 
Fig. (38). Chemical structure of aptiganel. 
 
In a dose-ranging, placebo-controlled, phase I study Muir 
et al., [1994] confirmed that aptiganel’s pharmacokinetic 
effects are favourable for a potential neuroprotective therapy.  
In human volunteers, however, dose-limiting effects of 
aptiganel were blood pressure increases and an excess of 
CNS. In another study both the safety and tolerability of ap-
tiganel were assessed in patients with acute ischemic stroke. 
It was demonstrated that a 4.5-mg intravenous bolus of apti-
ganel HCl followed by infusion of 0.75 mg/h for 12 h is a 
tolerable dose that can produce plasma drug concentrations 
shown to be neuroprotective in animal models [222]. Albers 
et al. [223] determined whether aptiganel improves the clini-
cal outcome in acute ischemic stroke patients. The com-
pound administered in the tested doses within 6 h of symp-
tom onset is not effective in the treatment of patients with 
acute ischemic stroke and may be harmful.  
As non-selective NMDA receptor antagonists have im-
peding adverse side effects, attention has been directed to-
wards compounds capable of modulating selectively certain 
subtypes of these receptors. In this field the NR2B-selective 
type of non-competitive antagonists has a strong potential, 
showing both analgesic and neuroprotective activity together 
with slight side effects [178, 224]. Many NR1/NR2B an-
tagonists, including ifenprodil, eliprodil and the selective and 
potent congeners, traxoprodil and Ro 25-6981, offer promise 
in preclinical models of ischemia [225-229]. 
Ifenprodil 
Ifenprodil (Fig. (39) NR2B selective NMDAR antago-
nist, when administered as a perfusion (0.3-3 mg/kg i.v.) 
over 3 hours after occlusion of the feline middle cerebral 
artery decreased the infarcted tissue volume (measured 4 
days after occlusion) in a dose-related manner. At the highest 
dose a 42% reduction of infarcted volume was observed, 
substantially in cortical tissue [225]. The interaction of com-
pound Ro 25-6981 (Fig. (39) with NMDA receptors proved 
that Ro 25–6981was more potent than ifenprodil [230].  
Eliprodil 
The neuroprotective activity of eliprodil (Fig. (40), 
NMDA receptor antagonist acting at the polyamine modula-
tory site, in brain trauma was examined in a rat model of 
lateral fluid-percussion brain injury. Eliprodil (10 mg/kg 
i.p.), reduced by 60% the volume of cortical damage. 
Moreover, the neuroprotective activity of the compound in 
experimental brain trauma using neuropathology was docu-
mented [226]. Eliprodil reduces lesion volume following 
traumatic brain injury [231]. 
Taxoprodil 
The neuroprotective effect of traxoprodil (Fig. (41) - a 
competitive NMDA antagonist at NR2B binding subunit, 
was evaluated in a rat subdural hematoma (SDH) model. The 
drug was infused 30 min after induction of SDH. The reduc-
tions of ischemic brain damage achieved by traxoprodil was 
29-37% [228]. Moreover, this drug exhibits a 69% reduction 
in infarct size in comparison to controls [232]. In humans it 
was well tolerated, penetrated the brain, and showed im-
provement in brain injury [232]. In a double-blind, placebo-
controlled study of the safety, tolerability and pharmacoki-
netics of traxoprodil in patients with a mild or moderate 
traumatic brain injury it had no psychotropic effects and was 
well-tolerated in patients [232]. Moreover, the compound 
had direct antiparkinsonian actions in rodents (decreased 
haloperidol-induced catalepsy with ED50=0.5 mg/kg) and 
monkeys (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MP 
TP)- treated monkeys, traxoprodil (1 mg/kg)) [233]. Moreo-
 
Fig. (39). Chemical structures of ifenprodil and Ro 25-6981. 
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Fig. (40). Chemical structure of eliprodil.  
 
Fig. (41). Chemical structure of traxoprodil.  
 
ver, no side effects were apparent at any dose of traxoprodil. 
The drug also reduced the maximum severity of levodopa-
induced dyskinesia approximately by 30% but it did not im-
prove Parkinsonism. Side effects were dose-related dissocia-
tion and amnesia [234], although in another study the drug 
was well tolerated, although no efficacy was seen in severe 
TBI [235]. 
Ro 63-1908 
Ro 63-1908 (Fig. (42) is a potent and highly selective an-
tagonist of the NR2B subtype of NMDA receptors, active 
versus sound-induced seizures (ED50=4.5 mg/kg i.p., DBA/2 
mice). It also inhibited NMDA-induced seizures with an 
ED50 =2.31 mg/kg i.v. In addition, Ro 63-1908 gave a dose-
related neuroprotective effect against cortical damage in a 
model of permanent focal ischemia. Maximum protection of 
39% was seen at a plasma concentration of 450 ng/ml. There 
were no adverse cardiovascular or CNS side-effects observed 
at these active doses [236]. 
 
Fig. (42). Chemical structure of Ro 63-1908. 
Amantadine 
Amantadine (Fig. (43), a low affinity NMDA antagonist 
represents an approach for treating Huntington’s disease 
[237]. Amantadine is also used as an adjuvant therapy in 
Parkinson’s disease. The compound exhibited efficacious 
effects in Parkinson's disease patients suffering from dyski-
nesias [238].  
 
Fig. (43). Chemical structure of amantadine. 
Memantine 
Memantine Fig. (44) is another low affinity NMDA re-
ceptor antagonist. The compound was tested for non-motor 
features of Parkinson’s disease and despite good tolerability 
the specific measures of sleepiness, fatigue, depression, and 
attention did not significantly improve [239]. It decreases 
probable REM sleep behavior disorder in patients with Park-
inson's disease dementia [240]. It leads to improvements in 
cognitive functions, stabilization of motor impairments, and 
decreases in the severity of mental disorders, especially in 
patients with hyperhomocysteinemia [241, 242]. 
Memantine has also been studied as a treatment for Alz-
heimer’s disease (AD). It was associated with slowing of 
right hippocampal atrophy, and with improvement on one 
test of executive functioning as well as a test of confronta-
tion naming ability [243].  
 
Fig. (44). Chemical structure of memantine. 
Dexanabinol 
Dexanabinol Fig. (45) belongs to non-competitive 
NMDA antagonists. Treated patients achieved significantly 
better intracranial pressure/cerebral perfusion pressure con-
trol without jeopardizing blood pressure. A trend toward 
faster and better neurologic outcome was also observed 
[244]. Further studies (phase III randomized, placebo-
controlled clinical trial) showed that dexanabinol is safe, but 
not efficacious in treatment of TBI [245]. 
 
Fig. (45). Chemical structure of dexanabinol. 
Remacemide 
Remacemide (Fig. (46) belongs to low affinity non-
competitive NMDA antagonists. The drug exerts anticonvul-
sant activity both in various animal seizure models and in 
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clinical studies. In addition, it seems to provide neuroprotec-
tion [246]. The antiepileptic effects include activity in ge-
netic absence epilepsy rats from Strasbourg (GAERS), and in 
an audiogenic rat model. The study showed the effects of 
remacemide in tonic/clonic seizure, which was the first target 
of the drug, and confirm the effect of the anticonvulsant on 
absence seizures [247]. Moreover, no serious adverse events 
were observed [248]. Pretreatment with remacemide has a 
moderate neuroprotective effect against status epilepticus-
induced neuronal damage [249].  
Remacemide hydrochloride might also improve symp-
toms of Parkinson’s disease by modulating glutamatergic 
overactivity in the basal ganglia or slow worsening by de-
creasing excitotoxicity. In rodent and primate models of 
Parkinson’s disease systemically administered compound has 
antiparkinsonian activity and low potential for side effects. It 
can be a safe and tolerable adjunct to dopaminergic therapy 
for patients with PD and motor fluctuations [250].  
 
Fig. (46). Chemical structure of remacemide. 
Neramexane 
Neramexane (Fig. (47) similarly to memantine, is an 
open-channel NMDA receptor blocker. The compound dis-
plays a similar pharmacokinetic and comparable clinical 
tolerability. It enhanced a long-term spatial (hippocampus-
dependent) memory in adult rats, thus it was concluded that 
may be helpful in treatment of dementia [251]. 
Dimebon 
Dimebon (Fig. (48) – an NMDA blocker at a site distinct 
from memantine, was initially classified as an antihistaminic 
drug. Systemic administration improves learning in animals 
with experimental model of Alzheimer's disease [252]. A 
randomised, double-blind, placebo-controlled study showed 
that dimebon was safe, well tolerated, and significantly im-
proved the clinical course of patients with mild-to-moderate 
Alzheimer's disease [253]. 
D-Cycloserine 
The antibiotic D-cycloserine (Fig. (49) is a partial glycine 
site agonist that improves glutaminergic activity in schizo-
phrenia. This preliminary evidence suggests that D-
cycloserine may improve negative symptoms and cognitive 
deficits over a narrow dose range when added to conven-
tional antipsychotic agents [254]. Studies confirmed poten-
tial role of D-cycloserine in the treatment of negative symp-
toms in schizophrenia. It was stated however that the degree 
of symptom reduction may be modest [255]. Preliminary 
studies with once-weekly administration showed that D-
cycloserine may play potential new role in schizophrenia by 
demonstrating benefit for negative symptoms, memory con-
solidation, and facilitation of cognitive behavioral therapy 
for delusions [256]. 
Felbamate 
Felbamate (Fig. (50) a non-competitive NMDA antago-
nist, showed a broad anticonvulsant profile similar to val-
proic acid when tested in experimental models. The com-
 
 
 
 
Fig. (47). Chemical structure of neramexane. 
 
Fig. (48). Chemical structure of dimebon. 
 
 
 
Fig. (49). Chemical structure of cycloserine. 
 
Fig. (50). Chemical structure of felbamate. 
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pound blocks NMDA receptors but fails to exhibit the neu-
robehavioral toxicity characteristic of other NMDA receptor 
antagonists. It exhibits modest selectivity for NMDA recep-
tors composed of NR1a/NR2B subunits. This selectivity 
could, in part, account for the more favorable clinical profile 
of felbamate in comparison with NMDA receptor antagonists 
that do not show subunit selectivity [257]. The studies indi-
cated that felbamate is an effective anticonvulsant drug in 
DBA/2 mice [258]. The in vitro antiepileptic activity of the 
novel anticonvulsant drug felbamate was tested in rat hippo-
campal slices on the CA1 epileptiform bursting induced by 
different chemical epileptogenic agents. 
6. ACID-SENSING ION CHANNELS 
Acid-sensing ionic channels (ASICs) are almost ubiqui-
tous in the mammalian nervous system, both at the periphery 
and in the brain [259]. They belong to H+-gated subgroup of 
the degenerin/epithelial Na+ channel (DEG/ENaC) family of 
cation channels [260]. In 1981, Krishtal and Pidoplichko 
described for the first time a receptor for H+ that carried in-
ward Na+ currents in mammalian sensory neurons [261, 
262]. The receptor was first cloned from the rat brain in 
1997, by the group of Lazdunski [263]. Then, receptor was 
crystallized in 2007 [264].  
ASICs appear to be the simplest of ligand-gated channels 
[263]. They are preferentially permeable to Na+, but to a 
lesser extent can also conduct other cations (e.g. Ca2+, K+, 
Li+ and H+). Individual subunits consist of two transmem-
brane domains, relatively short intracellular carboxy and 
amino termini and a large, cysteine-rich, extracellular do-
main [265, 260]. Investigation of the ASIC2a subunit 
showed that the pre-TM2 region is essential for pH sensitiv-
ity and gating [266]. ASICs are expressed in neurons and 
assemble into homomultimeric and heteromultimeric com-
plexes. It is not known precisely how many subunits are re-
quired to form a channel. Some researchers, by the analogy 
with other DEG/ENaC channels suggested four to nine ASIC 
subunits [267] More recent studies concerning crystallization 
of a chicken ASIC1 in low-pH proved homotrimeric struc-
ture, where each subunit of the chalice-shaped homotrimer is 
composed of short amino and carboxy termini, two trans-
membrane helices, a bound chloride ion and a disulphide-
rich, multidomain extracellular region enriched in acidic 
residues and carboxyl-carboxylate pairs within 3 Å, suggest-
ing that at least one carboxyl group bears a proton. Between 
the acidic residues and the transmembrane pore there is a 
disulphide-rich ‘thumb’ domain poised to couple the binding 
of protons to the opening of the ion channel, thus demon-
strating that proton activation involves long-range conforma-
tional changes [264, 268]. 
Individually expressed subunits form homomultimeric 
channels, whereas coexpression of 2 or more subunits allows 
formation of heteromultimeric channels. Surprisingly 
enough, ASIC2b does not form H+-gated channels when ex-
pressed alone but alters current properties when coexpressed 
with other ASICs. Coexpressing various subunits produces 
heteromultimers, with H+-gated currents revealing character-
istics that in some cases reflect ‘average’ properties of con-
tributing subunits and in other cases properties that lie out-
side the range of the individual subunits (e.g. rate of desensi-
tization). Subunit composition also alters ion selectivity; for 
example ASIC1a homomultimeric complexes are permeable 
to Ca2+, whereas ASIC2-containing heteromultimeric com-
plexes are not [260]. 
In heterologous cells, ASIC homomultimeric channels 
vary in terms of activation and desensitization kinetics as 
well as pH sensitivity. For example, in one study, the pH 
values required for half-maximal activation of murine ASIC 
subunits were 6.8 (ASIC1a), 6.2 (ASIC1b), 4.9 (ASIC2a) 
and 6.6 (ASIC3) [269, 270]. 
Activation and desensitization of ASICS occurs in re-
sponse to extracellular acidification. The channels formed by 
the ASIC proteins are proton-gated cation channels, opening 
rapidly in the presence of extracellular acid. Opening of the 
ion pore could be accomplished by a concerted global rota-
tion of the TM2 helices. Their fundamental role appears to 
be acid transduction, converting an acidic extracellular envi-
ronment into a cellular signaling event, by allowing for the 
conduction of cations into the cell [271]. 
The underlying mechanism coupling proton binding in 
the extracellular region to pore gating is unknown, neverthe-
less the role of any ion channel in a disease process can often 
be distilled down into inappropriately increased or decreased 
activity.  
In the peripheral nervous system (PNS), ASIC function 
usually as sensory receptors, for example in specialized 
nerve endings. They were found in neurons innervating skin 
[265, 273, 274], heart [275], intestines – especially ASIC3 
[276], muscles [277], bones [278], eyes [279, 280], ears 
[281] and taste buds [282]. 
There are two suppositions about localization of ASICs 
in the brain. One of them locate ASICs at synapses but most 
likely they are situated in the post-synaptic membrane or 
throughout the neuron [283]. 
ASICs are associated with four genes (ASIC1, -2, -3, and 
-4) that encode for 6 subunits: ASIC1a, ASIC1b, ASIC2a, 
ASIC2b, ASIC3 and ASIC4 [260]. When expressed in het-
erologous systems, all subunits except ASIC2b and ASIC4 
can form functional homomultimeric channels with distinct 
electrophysiological and pharmacological properties. When 
co-expressed, the heteromultimeric channels may demon-
strate characteristics dramatically different from their ho-
momeric counterparts [284]. ASIC1 and -2; both have alter-
native splice transcripts: ASIC1a, -1b, -2a, and -2b. ASIC4 
has not been shown to produce or modulate proton-evoked 
current and remains the least understood subunit. 
The pluralism of nomenclature introduced by different 
groups of researchers can be confusing and should be sys-
tematized (Table 1). The terms involving ‘acid-sensing ionic 
channel’ (ASIC) could seem to be most advantageous. 
Sometimes, names indicate also the tissue specificity (e.g. 
the dorsal root ASIC, DRASIC) but it is still unclear whether 
H+ are, in fact, natural ligands of these peculiar receptor 
channels. ASICs belong to the family of amiloride-sensitive 
ENaC/DEG receptor channels, which determines their syno-
nyms as ‘X-NaC’. The ‘NaC’ in this abbreviation means 
‘sodium channel’ and ‘X’ is related to a basic feature of the 
protein (DEG – degenerin, B – brain, L – liver, I – intestine 
refers to the members of this family that are degenerin pro-
teins). It is easy to anticipate that the ASIC nomenclature is 
still not final [259].  
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Table 6. Types of Calcium Channels and their Antagonists [112, 118-119] 
Family Subfamily Subtype/Type Type Antagonist 
Cav1.1 L 
Cav1.2 L 
Cav1.3 L 
Cav1 
Cav1.4 L 
Nifedipine 
Amlodipine 
Cav2.1 P/Q - 
Cav2.2 N 
-conotoxin-MVIIA, ziconotide 
Pyrazolylpiperidine derivative 
HVA 
Cav2 
Cav2.3 R Lamotrigine 
Cav3.1 T 
Cav3.2 T LVA Cav3 
Cav3.3 T 
Ethosuximide 
Mesuximide 
 
Table 7. Nomancletures of ASICs 
Subunit Isoform Synonym 
ASIC1 ASIC1a 
ASIC , 
BNaC2  
 ASIC1b 
ASIC , 
BNaC2  
ASIC2 ASIC2a 
MDEG1, BNaC1 , 
BNC1 
 ASIC2b 
MDEG2, 
BNaC1 , 
BNC1 
ASIC3  
DRASIC, 
TNaC 
ASIC4  SPASIC 
Alternative nomenclature of ASICs: BNaC - Na channel in the brain; MDEG - mammalian degenerin; DRASIC - dorsal root ASIC; SPASIC, spinal cord ASIC; TNaC - testis [273, 
263, 285]. 
 
Table 8. Disorders in CNS Involving ASICs 
ASIC Subunit 
Disorder 
1 2 3 4 
Anxiety [283; 286, 287] +    
Autoimmune encephalitis [288] +    
Depression [289] +    
Epilepsy [290-292] + +  + 
Glioma [293] + +   
Huntington’s disease [294] + +   
Multiple sclerosis [295, 288] +    
Pain [272, 296-299] + +   
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Anxiety 
The primary function of the nervous system is to generate 
flexible behavior in a changing environment. The acid-
sensing ion channel 1a (ASIC1a) is abundantly expressed in 
the amygdala complex and other brain regions associated 
with fear [283, 286]. Other work has shown that the 
amygdala, a collection of nuclei buried in the temporal lobe 
of the brain, is essential for both innate and learned fear in 
rodents and humans [300]. In 2009, group of Ziemann 
proved that ASIC1a in amygdala take part in the appearance 
of fear by detecting a decrease in extracellular pH and trig-
gering cationic currents. They report that inhalation of car-
bon dioxide (CO2) – simulating suffocation - decreases the 
pH in the amygdala and yields freezing behavior in mice. 
Moreover, genetic deletion or pharmacological disruption of 
ASIC1a channel reduces fear associated with CO2 inhalation. 
This finding provides new insight into the mechanisms by 
which amygdala neurons detect threat and suggests a new 
role for amygdale chemosensation in learned fear [287].  
Depression 
Depression remains one of the most disabling medical 
diseases but the molecular pathways underlying depression 
are poorly understood, and existing treatments are too often 
ineffective. One of the brain part, the amygdala play a cen-
tral role in mood regulation. ASIC1a is expressed widely in 
the central and peripheral nervous systems and is robustly 
expressed in structures associated with mood including the 
amygdale. ASIC1a is required for acid-evoked currents in 
central neurons, where it contributes to synaptic plasticity 
and in the regulation of dendritic spines. Some preclinical 
screenings showed that genetically disrupting ASIC1a in 
mice produced antidepressant-like effects in the forced swim 
test, the tail suspension test, and following unpredictable 
mild stress. Pharmacologically inhibiting ASIC1a also had 
antidepressant-like effects in the forced swim test. The ef-
fects of ASIC1a disruption in the forced swim test were in-
dependent of and additive to those of several commonly used 
antidepressants [289]. 
Epilepsy 
There are some interesting insights in how ASICs inter-
act epilepsy and seizures. One of them showed that acid-
sensing ion channel 1a (ASIC1a) activation enhances neu-
ronal excitability in the hippocampus and neocortex, indicat-
ing that ASIC1a might play a role in the generation and 
maintenance of epileptic seizures [292]. Other publication 
mentioned that ASICs’ inhibitor – amiloride neither altered 
the threshold for electroconvulsions, nor protected the ani-
mals against MES-induced seizures in mice but amiloride 
administered 75 and 100 mg/kg, i.p., 120 min prior to the 
test significantly enhanced the anticonvulsant effects of car-
bamazepine, oxcarbamazepine and phenobarbital, by reduc-
ing their ED50 values in the MES test [291]. On the other 
hand, there was also established that seizures reduce ex-
tracellular pH. Extracellular acidosis, in turn, activates 
ASIC1a, which terminates seizure activity [290]. 
Glioma 
Gliomas are primary brain tumors with a complex biol-
ogy characterized by antigenic and genomic heterogeneity 
and a propensity for invasion into normal brain tissue. High 
grade glioma cells possess a voltage-independent, amiloride-
inhibitable, inward Na-current. This current does not exist in 
normal astrocytes or low grade tumor cells. Inhibition of this 
conductance decreases glioma growth and cell migration 
making it a potential therapeutic target. Some results have 
shown that the acid-sensing ion channels (ASICs especially 
ASIC2), are part of this current pathway [293].  
Huntington’s Disease 
Huntington's disease (HD) is a neurodegenerative genetic 
disorder that affects muscle coordination and leads to cogni-
tive decline and psychiatric problems. Some HD models 
have been studied, where amiloride derivative benzamil 
(Ben), a chemical agent used to rescue acid-sensing ion 
channel (ASIC)-dependent acidotoxicity, was examined 
whether chronic acidosis is an important part of the HD 
pathomechanism and whether these drugs could be used as 
novel therapeutic agents. Ben markedly reduced the hunting-
tin-polyglutamine (htt-polyQ) aggregation in an inducible 
cellular system, and the therapeutic value of Ben was suc-
cessfully recapitulated in the animal model of HD [294]. 
Multiple Sclerosis 
Multiple sclerosis is one of the most common causes of 
progressive disability affecting young people. Multiple scle-
rosis is a neuroinflammatory disease associated with axonal 
degeneration. The neuronally expressed, proton-gated acid-
sensing ion channel-1 (ASIC1) is permeable to Na+ and Ca2+, 
and excessive accumulation of these ions is associated with 
axonal degeneration. ASIC1 are hypothesized to contributes 
to axonal degeneration in inflammatory lesions of the central 
nervous system (CNS). In this context, ASIC1’s blockers 
could provide neuroprotection in multiple sclerosis [295]. 
According to some researches, blocking ASIC1 with amilo-
ride protected both myelin and neurons from damage in the 
acute model, and when given either at disease onset or, more 
clinically relevant, at first relapse, ameliorated disability in 
mice with chronic-relapsing experimental autoimmune en-
cephalomyelitis [288]. 
Pain 
Tissue acidosis is a common feature of many painful 
conditions. Protons are indeed among the first factors re-
leased by injured tissues, inducing a local pH decreasing that 
depolarizes peripheral free terminals of nociceptors and leads 
to pain. ASICs are excitatory cation channels directly gated 
by extracellular protons that are expressed in the nervous 
system. At the peripheral level, ASIC3 is important for in-
flammatory pain. At the central level, ASIC1a is largely ex-
pressed in spinal cord neurons where it has been proposed to 
participate in the processing of noxious stimuli and in central 
sensitization. Blocking ASIC1a in the spinal cord also pro-
duces a potent analgesia. Targeting ASIC channels at differ-
ent levels of the nervous system could therefore be an inter-
esting strategy for the relief of pain [272]. Pharmacological 
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Fig. (51). (A) Schematic concentration of an ASIC unit, (B) 
Trimeric organization of a functional ASIC channel (TM1 and 
TM2 tramsmembrane domains 1 and 2) [272]. 
 
 
 
 
 
 
Fig. (52). Chemical structure of benzamil.  
 
 
 
Fig. (53). Chemical structure of amiloride.  
 
Fig. (54). Chemical structure of A -317567.  
 
block of ASIC1a activity by the PcTx1 injected intrathecally 
produces strong analgesic effects in several rodent models of 
acute and chronic pain. The genetic knockdown of ASIC1a 
expression by intrathecal delivery of antisense oligonucleo-
tides produces similar analgesic effects [296, 297].  
Amiloride 
In the great majority of studies, amiloride has been used 
to block ASIC, but is a weak blocker, especially in contrast 
to its affinity for ENaCs (10–100-fold higher). 
Aminoglycosides (AGs) 
Aminoglycosides (AGs) are a group of antibiotics whose 
structure is based on aminocyclitol rings interconnected by 
glycosidic bonds. Some studies showed that AGs may con-
stitute a valuable tool for the modulation of ASICs, and may 
be a feasible starting point for the development of new mole-
cules structurally related to the AGs but with a greater affin-
ity, specificity, and selectivity for the different ASIC 
subunits [306]. 
APETx2 
APETx2 is a novel peptide toxin isolated from sea anem-
one venom, which selectively inhibits homomeric ASIC3 
channels as well as the ASIC1+3, ASIC1b+3, and ASIC2b+3 
heteromers. APETx2 is a basic peptide (pI = 9.59) of 42 
amino acids, cross-linked by three disulfide bridges. The 
discovery of a toxin with ASIC3-blocking activity is of ma-
jor significance given the substantial amount of evidence 
now implicating this channel in the transduction of acid-
induced pain and hyperalgesia [303]. 
A-317567 
A-317567 is a novel non-amiloride ASIC blocker with 
distinct mode of action and improved potency both in vitro 
and in vivo over amiloride. A-317567 blockes ASIC-like 
currents in cultured dorsal root ganglion neurons [301] and 
cultured cortical neurons [289]. While further evaluation of 
the mechanism of action of A-317567 is required to fully 
understand its mode of action, this compound will provide a 
new tool for investigating ASIC biology, physiology, and 
pathophysiology [301]. 
Diaminazene 
Aromatic diamidines (Fig. 55) are DNA-binding agents 
and have long been used in the treatment of leishmaniasis, 
trypanosomiasis, pneumocystis pneumonia and babesiosis. 
Moreover, some aromatic diamidines are used as skin-care 
and baby products and others have potential to suppress tu-
mor growth or to treat malaria. The application of aromatic 
diamidines is not limited to anti-parasitics. Recently, it was 
found that aromatic diamidines such as pentamidine, hy-
droxystilbamidine, and diminazene potently block ASICs 
[305]. Each of these compounds inhibited ASIC currents, 
indicating that the linker in each of these diamidines can be 
variable, while the amidine group linked with an aromatic 
moiety appears to be essential. Among them, diminazene 
blocks ASICs with an IC50 of 0.3 μM, being the most potent 
small molecule inhibitor of ASICs. Moreover, diminazene 
inhibits sensory neuron-specific ASIC1b more strongly than 
any other ASIC subunits. 3μM diminazene almost com-
pletely blocks ASIC1b [311]. 
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Fig. (55). Chemical structures of aromatic diamidines [305]. 
 
 
Fig. (56). Chemical structure of nafamostat. 
Nafamostat 
Nafamostat (Futhan, FUT-175) is a synthetic, competi-
tive, reversible serineprotease inhibitor. Therefore, nafamo-
stat functions as an anti-inflammation and anti-coagulation 
agent. It is clinically used, mainly in the East Asia, for the 
treatment of disseminated intravascular coagulation, acute 
pancreatitis, and as an anticoagulant in extracorporeal circu-
lation. Nafamostat, like aromatic diamidines, is also a highly 
polarized, linear di-cationic agent governed by an amidine 
group at one terminus and a guanidine group at the other. 
Recently, nafamostat blocks ASICs heterogeneously ex-
pressed in Xenopus oocytes with an IC50 of 2–70 μM de-
pending on the ASIC subtype [307]. 
Nonsteroid Anti-inflammatory Drugs (NSAIDs) 
Nonsteroid anti-inflammatory drugs (NSAIDs) (Fig. (57) 
are major drugs against inflammation and pain. They are 
well known inhibitors of cyclooxygenases (COXs). How-
ever, many studies indicate that they may also act on other 
targets such as ASICs. There were proposed that the two 
effects, i.e., direct channel block and inhibition of inflamma-
tion-induced ASIC expression, play an important role in the 
antinociceptive effects of NSAIDs in addition to their well 
known effects on COXs and more particularly in case of 
inflammation [304]. 
PcTx1 
The first selective inhibitor of ASIC1a was Psalmo-toxin 
1 (PcTx1). It was purified from the venom of the tarantula 
Psalmopoeus cambridge [308]. PcTx1 is a 40 amino acid 
peptide crosslinked by three disulfide bridges, it has a mo-
lecular mass of 4689.40 Da.  
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Fig. (57). Chemical structures of some NSAIDs. 
 
PcTx1 inhibit similarly homomeric ASIC1a channels in 
various cell expression systems with a very high affinity (see 
Table 9). PcTx1 inhibits ASIC1a by increasing its apparent 
affinity for H+. PcTx1 affinity for ASIC1a depends on ex-
tracellular pH and is the highest in pH=7.4. However, the 
mechanism by which PcTx1 increases the apparent H+ affin-
ity remains unclear [312]. PcTx1 also interacts with ASIC1b, 
a splice variant of ASIC1a. However, PcTx1 does not inhibit 
ASIC1b but promotes its opening; under slightly acidic con-
ditions, PcTx1 behaves like an agonist for ASIC1b [313]. At 
Table 9. Binding Affinities of Known ASIC Ligands 
Ligand Subunit IC50 
A-317567 [301] 
ASIC1 
ASIC2 
ASIC3 
2.0 μM 
29.1 μM 
9.5 μM 
Amiloride 
[263, 301-302] 
ASIC1a 
ASIC1b 
ASIC2a 
ASIC3 
ASIC3 
10 μM 
21 μM 
0.15 μM 
37.2 μM 
63.0 μM 
APETx2 
(Sea anemone toxin) 
[303] 
ASIC3 
ASIC1a+3 
ASIC1b+3 
ASIC2b+3 
63.0 nM 
2.0 μM 
0.9 μM 
117.0 nM 
Acetylsalicylic acid 
[304] 
ASIC3 260 μM 
DAPI 
[305] 
ASIC in hippocampal neurons 2.8 μM 
Diclofenac [304] ASIC3 92 μM 
Diminazene [305] ASIC in hippocampal neurons 0.3 μM 
Flurbiprofen [304] ASIC1a 350 μM 
Gentamycin [306] ASIC in dorsal root ganglion neurons 44 μM 
Hydroxystilbamidine 
[305] 
ASIC in hippocampal neurons 1.5 μM 
Ibuprofen [304] ASIC1a 350 μM 
Nafamostat [307] ASIC depending on the subunit 2-70 μM 
Neomycin [306] ASIC in dorsal root ganglion neurons 32 μM 
PcTx-1 
(Tarantula toxin, 
psalmotoxin 1) 
[308-310] 
ASIC1a 0.9 nM 
Pentamidine [305] ASIC in hippocampal neurons 38 μM 
Synthalin [305] ASIC in hippocampal neurons 29 μM 
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the molecular level, it was suggested that the ion pore struc-
ture, constituted by trans-membrane M1 and M2 segments 
and intracellular pre-M1 and post-M2 regions (Fig. (58), are 
not directly involved in either the PcTx1 binding site or in its 
mechanism of inhibition. Amiloride, a known pore blocker 
of ENaC/DEG/ASIC channels, does not inhibit PcTx1 bind-
ing, which also supports this conclusion. PcTx1 binds prin-
cipally on both cysteine-rich domains I and II (CRDI and 
CRDII) of the extracellular loop; the post-M1 and pre-M2 
regions, although not involved in the binding site, are crucial 
for the ability of PcTx1 to inhibit ASIC1a current by modifi-
cation of channel gating; the linker domain between CRDI 
and CRDII is important for their correct spatial positioning 
to form the PcTx1 binding site [310].  
7. TRANSIENT RECEPTOR POTENTIAL (TRP) 
CATION CHANNELS 
The superfamily of transient receptor potential (TRP) 
cation channels function as cellular sensors of various extra- 
and intracellular environmental changes. The first member of 
TRP channels was identifed in 1969 (by Cosens and Man-
ning) in Drosophila mutants that displayed a transient re-
sponse to light [314]. The family of transient receptor poten-
tial canonical (TRPC) proteins was the first group of TRP 
homologs cloned in mammals after discovery of the TRP 
protein in Drosophila [315].  
The TRP channels comprises of five families (TRPA, 
TRPC, TRPM, TRPN and TRPV) and two subfamilies 
(TRPML and TRPP), which share several key properties: 
they are nonselective cation channels and most have six 
transmembrane domains [316, 317]. They are also divided 
into subtypes (Table 10) [318]. 
It was determined that, TRPs are tetrameric cation chan-
nels [319]. Each channel subunit contains six transmembrane 
segments (S1–S6) and a pore-forming region formed by a 
loop between the S5–S6 segments. Both the amino (N) ter-
minus and the carboxyl (C) terminus are located intracellu-
larly. Most of the TRP channels have an N-terminal ankyrin 
repeating domain and a C-terminal TRP domain. The long N 
and C termini of TRPs also contain several additional regula-
tory domains which are relatively conserved in most of the 
TRPs (Fig. (59) [314]. 
TRPA (ankyrin) family has one member: TRPA1 which 
contributes to the detection of intense mechanical stimuli. It 
has a characteristic large number of ankyrin protein repeats, 
thought to act as a spring and intracellular anchor, which 
may contribute to mechanosensory transduction. It responds 
to a range of environmental irritants e.g. formaline, extracts 
of mustard, cinnamon, garlic, oregano [321-323]. TRPA1 is 
localised in gastro-oesophageal vagal afferents, splanchnic 
colonic afferents and pelvic colonic afferents [316].  
There are seven members in this family (TRPC1–7). The 
TRPC channels formed by homo- or heteromeric TRPC pro-
teins are Ca2+-permeable nonselective cation channels. Ac-
cording to the similarity in amino acid sequence, the mam-
malian TRPCs can be classified into four subgroups: 
 
Fig. (58). PcTx1 binding site on ASIC1a channel. 
 
Table 10. Classification of TRP Channels 
 Type Name Subtype 
TRPA Ancyrin TRPA1 
TRPC Canonical TRPC1-7 
TRPM Melastatin TRP1-8 
TRPN No mechanorecepor potential  
Fa
m
il
ie
s 
TRPV Vanilloid TRP1-6 
TRPP Policystin TRPP1-3, 5 
Su
bf
am
il
ie
s 
TRPML Mucolipin TRPML1-3 
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TRPC1, TRPC2, TRPC3/6/7, and TRPC4/5, while the 
TRPC2 is a pseudogene in primates. The TRPC proteins 
have six transmembrane domains, and both N- and C-termini 
of these proteins are intracellular, suggesting that these 
channels can be regulated by intra cellular signaling mole-
cules [324]. These channels can be activated in various cell 
types by G-protein-coupled receptors (GPCR) and receptor 
tyrosine kinases (RTK) through a phospholipase C (PLC)-
dependent mechanism. Therefore, TRPC channels may act as 
a sensor for environmental cues. In mammals, they were 
found in brain, heart, testis, ovaries, lung, retina, endothelia 
and adrenal glands. They partake in multiple physiological 
functions such as neuronal excitability in Purkinje cells, 
acrosome reaction in sperm cells, pheromone response, 
vasorelaxation and neurotransmitter release. They represent 
an important Ca2+ source for cells and have also been associ-
ated with Ca2+ oscillations [325]. 
 
 
Fig. (59). Schematic structure of TRP channels [320]. 
 
TRPM subunits are localized in dorsal root ganglion neu-
rons, taste buds, gut epithelium, brain, kidney, heart, pros-
tate, intestine, liver and lung [325, 326]. TRPM family is 
now widely researched because it mediates the cooling and 
soothing sensation of e.g. menthol and eucalyptol. In this 
context, TRPM8 may be critical in alleviating pain [316].  
The TRPN family has not been detected in mammals, but 
is present in Drosophila, zebrafish and worm. It has been 
proposed to be sensitive to mechanical stimuli and is ex-
pressed in mechanosensory neurons of the ear and eye [327]. 
The TRPV, also called vanilloid family, is probably the 
best known subfamily of TRP channels, notably TRPV1 
which is activated by the vanilloid chilli extract capsaicin. 
They are localized in neurons innervating gut, colon, stom-
ach, skin, urinary bladder, spleen, liver, placenta, kidney, 
lung and testis [317, 325, 316]. 
The polycystin, or TRPP family has four members, 
TRPP1, 2, 3 and 5. Their name is derived from an associa-
tion between a TRPP mutation and polycystic kidney dis-
ease. They play roles in developmental guidance and ciliary 
function. They recently received interest in connection with a 
role in acid sensing [316]. 
The mucolipin, or TRPML family has three members, 
one of which is associated with mucolipidosis. They have an 
intracellular function putatively in vesicle formation [316].  
Alzheimer’s Disease 
Cognitive impairment and emotional disturbances in 
Alzheimer's disease (AD) result from the degeneration of 
synapses and neuronal death in the limbic system and associ-
ated regions of the cerebral cortex. Some indications suggest 
a role for TRPC6 in Alzheimer’s disease. Mutations in the 
presenilin genes are linked to the development of early-onset 
Alzheimer’s and transient expression of presenilin mutants 
(N141I, M239V) along with TRPC6 in human embryonic 
kidney - 293 cells results in a strong inhibition of agonist (1-
oleoyl-2-acetyl-sn-glycerol (OAG) and angiotensin II (Ang 
II)) induced Ca2+ entry. Interestingly, the loss of function PS 
mutant D263A augments the activity of TRPC6 [328, 329]. 
Bipolar Disorder 
The pathophysiology of bipolar disorder has been con-
nected to a variety of TRP channels. Findings of Goedding 
and coworkers implicate the calcium-permeable TRPM2 and 
canonical TRPC3 in the pathogenesis of bipolar disorder 
(BD). These channels are involved in calcium and oxidative 
stress signaling, both of which are disrupted in BD. Thus, 
authors sought to determine if these channels were differen-
tially affected by oxidative stress in cell lines of BD patient 
origin using B lymphoblast cell lines from bipolar I disorder 
(BD-I) patients, the oxidative stressor and TRPM2 and 
TRPC3 respective activators H2O2 and OAG. Data support 
an important role for TRPM2 and TRPC3 in sensing and 
responding to oxidative stress and in transducing oxidative 
stress signaling to intracellular calcium homeostasis and cel-
lular stress responses, all of which have been implicated in 
the pathophysiology of BD [330]. It is also worth mentioning 
in connection with depressive mental disorders that leptin, 
which is connected to TRPC1 (and probably also TRPC3), 
has antidepressant effects and that impaired leptin production 
contributes to depression-like phenotypes in a rat model 
[331]. 
Ischemic Stroke 
It is known that restoring extracellular Ca2+ following a 
period of low Ca2+ concentrations paradoxically causes an 
increase in intracellular Ca2+ levels that can lead to cell 
death. The mystery of this ‘Ca2+ paradox’ is made more in-
triguing by observations that lowering concentrations of ex-
tracellular Ca2+ and/or Mg2+ paradoxically enhances the en-
try of Ca2+ into hippocampal neurons. Some research con-
cluded that extracellular Ca2+ and Mg2+ are important regula-
tors of intracellular Ca2+, through their modulation of 
TRPM7 and potentially other non-selective cation channels 
such as TRPM2 [332, 333]. 
Parkinson’s Disease 
1-Methy-4-phenylpyridium (MPP1) induces Parkinson 
disease-like syndromes. When applied to human dopaminer-
gic SH-SY5Y neuroblastoma cells, MPP1 causes decreased 
expression and plasma membrane localization of TRPC1. In 
an opposite manner, TRPC1 overexpression reduces the neu-
rotoxicity of MPP1. Some studies showed that activation of 
TRPC1 by thapsigargin or carbachol decreased MPP1 neuro-
toxicity Thus TRPC1 may execute a neuroprotective role in 
dopaminergic neurons. Furthermore, TRPC1 may inhibit 
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Fig. (60). Chemical structure of OAG. 
 
Fig. (61). Chemical structure of angiotensin II. 
 
Fig. (62). Chemical structure of thapsigargin. 
 
 
 
 
 
 
 
 
 
Fig. (63). Chemical structure of carbachol. 
 
degenerative apoptotic signaling to provide neuroprotection 
against Parkinson’s disease-inducing agents [334, 335]. 
 
Fig. (64). Chemical structure of pinokalant (LOE 908) [340, 341]. 
 
Schizophrenia 
Schizophrenia is a chronic, debilitating psychiatric disor-
der that afflicts people of all races and carries a life-time risk 
of the order of 1%. Schizophrenia is accompanied by mor-
phological changes in the brain that include enlarged ventri-
cles, a reduced cortical thickness, but an increased prefrontal 
neuron density. Patients also exhibit reduced pain sensitivity 
and a diminished niacin skin flare response. The latter symp-
toms hint towards a defect in TRPV1-expressing afferent 
nerve fibers. Direct evidence for links between schizophrenia 
and TRP channels is lacking. However, several aspects of the 
pathophysiology of the disorder point to a possible involve-
ment of TRP channels. Links between TRP channels and 
schizophrenia with respect to neurodevelopment, dopa-
minergic and cannabinoid systems, thermoregulation, and 
sensory processes, are still discussed. Investigation of these 
links holds the prospect of a new understanding of schizo-
phrenia with resultant therapeutic advances [336, 337]. 
Traumatic Brain Injury (TBI) 
Traumatic brain injury classically results from mechani-
cal injury induced by physical impact or a rapid change in 
acceleration/deceleration of the head. TBI can quickly lead 
to dysfunction of the microvessel endothelial cells in brain, 
including disruption of blood–brain barrier (BBB). It is now 
evident that elevation of cytosolic calcium levels [Ca2+]i can 
compromise the BBB integrity, however the mechanism by 
which mechanical injury can produce a [Ca2+]i increase in 
brain endothelial cells is unclear. Ca2+ is a ubiquitous second 
messenger that plays key roles in the regulation of cellular 
processes such as gene expression, secretion and apoptosis. 
Ca2+ channels are of particular interest in cell proliferation 
because of the profound anti-proliferative effect seen when 
extracellular Ca2+ is removed. Evidence from studies of 
many cell types indicates that Ca2+ entry mechanisms have 
an essential role in this effect. The concentration of Ca2+ is 
carefully controlled through the regulation of a variety of 
membrane channels and pumps including TRP channels 
[338]. It was stated that blockade of TRPC1 and TRPP2 both 
by chemical inhibitors (amiloride, LOE908) and by siRNA 
knockdown assays directed at TRPC1 and TRPP2 expression 
abolished the injury transient [Ca2+]i increase. Taking into 
account these fact it can be stated that mechanical injury of 
brain endothelial cells induces a rapid influx of calcium, me-
diated by TRPC1 and TRPP2 channels [339]. 
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8. GABA RECEPTORS 
GABA ( -aminobutyric acid) is the most abundant in-
hibitory neurotransmitter found in the mammalian CNS, 
where about 20% of all neurons are GABAergic [342]. 
GABA acts by binding to two different types of receptors, 
ionotropic receptors (GABAA and GABAc) and metabotropic 
receptors (GABAB). Two GABA receptors subfamilies 
GABAA and GABAC differ in their ability to form endoge-
nous heteromeric and homomeric receptors and in their 
physiological and pharmacological properties [343].  
GABAA, as ligand-gated ion channels, facilitate rapid re-
sponses. Activation leads to two types of GABAergic inhibi-
tion: phasic and tonic inhibition. Classical phasic GABAA 
receptor-mediated inhibition is produced by brief exposure 
of postsynaptic GABAA receptors to high concentrations of 
GABA. On the other hand, tonic GABAA receptor-mediated 
inhibition results from the activation of extrasynaptic recep-
tors by low concentrations of ambient GABA [344]. In many 
regions of the brain GABAA receptor-mediated currents are 
dominated by tonic currents, which account for about 75%-
90% of total inhibitory currents [345].  
GABAA receptors (Fig. (65) are a heterogeneous family of 
ligand-gated ion channels that mediate inhibitory neuro-
transmission in the CNS. They are assembled from five 
subunits in a heteropentameric chloride ion channels. Vari-
ous GABAA receptor subunit subtypes as well as splice vari-
ants can be distinguished, such as 1- 6, 1- 3, 1- 3, , ,  
and . Each GABAA receptor subunit is composed of a long 
extracellular N terminus, four transmembrane domains (M1-
M4), one extracellular M2-3 loop, two intracellular loops 
(M1-2 and M3-4) and a short extracellular C terminus.  
 
 
Fig. (65). Schematic structure of GABAA receptor. 
 
 and  receptors are the principal isoforms present 
in vivo [346]. The most omnipresent and predominant synap-
tic receptor in the brain is 1 2 2 isoform [347]. The  
GABAA receptors are localized extra- or perisynaptically and 
mediate GABAergic tonic inhibition. In comparison with 
synaptically localized  receptors,  receptors are more 
sensitive to GABA, show relatively slower desensitization 
and display lower efficacy to GABA agonism [348]. A lot of 
studies have implicated the important role of tonic inhibition 
in neuronal excitability mediation under physiological condi-
tions.  
Recent studies have demonstrated that defects in  re-
ceptor function or tonic inhibition resulted in neurological 
disorders such as epilepsy [349, 350]. Studies regarding the 
genetics of human epilepsy demonstrated that various herita-
ble mutations in GABAA receptor subunits are associated 
with epilepsy [351]. It is well established that activation of 
GABAA receptors plays an important role in sleep [352]. It 
was indicated that especially 3 GABAA receptor subunit is 
involved in this condition [353].  
Aside from epilepsy and sleep disturbances there are a 
number of pathological conditions for which GABAA recep-
tors represent vital therapeutic targets such as anxiety disor-
ders, cognitive disorders, moods disorders and schizophrenia 
[354]. 
GABAA receptor, apart from response to GABA, can be 
also allosterically regulated by an increasing number of 
agents such as benzodiazepines (BZs), barbiturates, anticon-
vulsants and anesthetics [355]. Three distinct binding sites 
present on GABAA receptors were identified: GABA/ mus-
cimol, t-butylbicyclophosphorothionate (TBPS)/picrotoxin, 
and benzodiazepine [356]. 
GABAA receptors are omnipresent in the CNS. Thus, the 
current goal in neuropharmacology is to target drugs selec-
tively to defined GABAA receptor subtypes. This new strat-
egy may help to improve the therapeutic spectrum of the 
presently available drugs and indicate new therapeutic indi-
cations. Additionally, such subtype-specific drugs are ex-
pected to display fewer concomitant unwanted effects, as 
they influence only a small population of GABAA receptors.  
As the number of compounds interacting with GABAA 
receptors is impressive a complete coverage of all of them 
within this review would be difficult. Then, only recently 
developed compounds showing efficacy at GABAA receptors 
is presented.  
SL651498 
SL651498 (Fig. 66) a pyridoindole derivative is a full 
agonist at GABAA receptors containing 2 and 3 subunits 
and a partial agonist at GABAA receptors containing 1 and 
5 subunits. The compound showed anxiolytic-like activity 
similar to that of diazepam (minimal effective dose (MED): 
1-10 mg/kg, i.p.) in conflict models such as the elevated 
plus-maze, the light/dark test, and the defense test battery in 
rats and mice. Additionally, the study indicated that 
SL651498 produced ataxia, muscle weakness or sedation at 
doses much higher than those producing anxiolytic-like ac-
tivity. No appearance of tolerance to its anticonvulsant ef-
fects or physical dependence was observed in mice [357]. 
SL651498 elicits anxiolytic-like effects similar to conven-
tional BZs. The compound also fully induced muscle relaxa-
tion but in contrast to classical BZs produced minimal ataxia 
in monkeys [358]. The highest dose of SL651498 demon-
strated slight effects on saccadic peak velocity (SPV) and 
smooth pursuit performance, albeit to a much lesser extent 
than lorazepam. Additionally, in contrast to lorazepam, none 
of the SL651498 doses influenced visual analogue scale 
alertness, body sway, attention, or memory tests [359].  
MRK-409 
MRK-409 (Fig. (37) also known as MK-0343 was origi-
nally designed to be a less sedating anxiolytic, based on re-
duced efficacy at the 1 subtype and significant efficacy at 
2 and 3 subtypes of the GABAA receptor. The anxiolytic-
like and sedative activity was observed at minimum effective 
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Fig. (66). Chemical structure of SL651498. 
 
Fig. (67). Chemical structure of MRK-409. 
 
doses corresponding to occupancies, depending on the model 
used, ranging from about 35% to 65% yet there were mini-
mal overt signs of sedation at occupancies greater than 90% 
[360]. MK-0343 at 0.75 mg in humans was equipotent with 
lorazepam, on the other hand diminished effects on memory 
and postural stability were observed. 0.25 mg dose only in-
fluenced postural stability to a similar extent as MK-0343 
0.75 mg [361]. Recent studies showed that treatment with 
MRK-409 leads to sedation in humans at a dose (2 mg) cor-
responding to the levels of occupancy considerably less than 
those predicted formerly in rodent models to be required for 
anxiolytic activity. It was concluded that the preclinical non-
sedating anxiolytic profile of MRK-409 could not be trans-
lated into humans and further development of the compound 
was halted. 
BL-1020 
BL-1020 (Fig. (68) is a novel, orally bioavailable ester of 
perphenazine and GABA. Unlike first- and second-
generation antipsychotics, it has agonist activity at GABAA. 
Compound’s efficacy in acute and subchronic schizophrenia 
rat models was evaluated by Geffen et al. [362]. The study 
showed that acute and subchronic treatment with BL-1020 
antagonized amphetamine-induced hyperactivity, with sig-
nificantly lower catalepsy and sedation compared to equimo-
lar perphenazine. Phase-II, open-label study suggested that 
20 to 40 mg/d of BL-1020 is associated with clinically rele-
vant improvement of psychosis with no worsening of ex-
trapyramidal symptoms (EPS) [363]. Fitzgerald [364] sum-
marized clinical trials of BL-1020 and concluded that the 
compound was well tolerated in all trials conducted, and 
clinically meaningful improvements were demonstrated in 
phase II trials in patients with schizophrenia. 
 
 
Fig. (68). Chemical structure of BL-1020. 
L-838417 
L-838417 (Fig. (69) is the novel benzodiazepine site 
ligand, a partial agonist at GABAA receptors containing an 
2, 3 or 5 subunit and an antagonist at 1 receptors, giving 
an anxiolytic profile devoid of sedation [365, 366]. It showed 
anxiolytic-like activity in wild-type rats as shown in the ele-
vated plus-maze test and in a conditioned fear-potentiated 
startle protocol. Significant motor effects were not observed 
[367]. L-838417 was also anxiolytic in murine Vogel con-
flict test [368]. Additionally, the compound exhibited anti-
convulsant activity [369].  
 
 
Fig. (69). Chemical structure of L-838417. 
 
TPA-023 
TPA-023 (Fig. (70) is an agonist selective for 2 and 3-
containing GABAA receptors. In unconditioned (elevated 
plus maze) and conditioned (fear-potentiated startle and con-
ditioned suppression of drinking) rat models of anxiety the 
compound showed anxiolytic-like activity with minimum 
effective doses (MED; 1–3 mg/kg) corresponding to 70 to 
88% occupancy. No appreciable sedation was stated in a 
response sensitivity (chain-pulling) assay at a dose of 30 
mg/kg. The compound elicited anxiolytic effect in the squir-
rel monkey conditioned emotional response assay (MED of 
0.3 mg/kg), however, it was not able to produce any sedation 
in a lever-pressing test of sedation. Finally, TPA-023 showed 
anticonvulsant activity in a mouse pentylenetetrazole seizure 
model [370]. TPA-023 had significant dose dependent ef-
fects on saccadic peak velocity that approximated the effects 
of lorazepam [371]. However in contrast to lorazepam, TPA-
023 had no detectable effects on saccadic latency or inaccu-
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racy. In addition unlike lorazepam, TPA023 did not affect 
VAS alertness, memory or body sway.  
 
 
Fig. (70). Chemical structure of TPA-023. 
 
Indiplon (Fig. (71) is a high-affinity allosteric potentiator 
of GABAA responses that demonstrates preference for 1 
subunit-containing GABAA receptors. The compound is stud-
ied for the treatment of insomnia. A double-blind, placebo-
controlled trial investigated the efficacy and safety of modi-
fied-release indiplon in elderly patients with chronic insom-
nia. The study demonstrated that indiplon (15 mg), was well 
tolerated and significantly improved all patient-reported 
measures of sleep during the of treatment [372]. Long-term 
(3 months) nightly treatment with the drug (10 mg and 20 
mg) has confirmed its efficacy in sleep onset, maintenance, 
and duration [373]. Indiplon’s activity was also confirmed in 
healthy volunteers in a model of transient insomnia [374].  
 
 
Fig. (71). Chemical structure of indiplon. 
 
Y-23684 
Y-23684 (Fig. (72) is pyridazinone derivative and selec-
tive partial agonist at BZ receptors. The compound is highly 
suggested to be a potent and selective anxiolytic agent with 
fewer side effects than classical BZ-anxiolytics. Studies 
comparing the pharmacological properties of Y-23684 with a 
classical benzodiazepine agonist diazepam demonstrated that 
in rat conflict tests (Geller-Seifter and water-lick tests), Y-
23684 showed an antipunishment action at doses 2-4 times 
lower than diazepam and was at least as efficacious as diaze-
pam in rodent models of anxiety (social interaction and ele-
vated plus-maze tests). In a mouse model of anxiety (explo-
ration (light/dark box) test), Y-23684 was two fold less ef-
fective as diazepam. In these paradigms, the compound 
demonstrated a selective anxiolytic activity over a wide 
dose-range without loss of efficacy and sedative action. Fur-
ther studies with Y-23684 proved that the impairment of 
motor coordination (rotarod) and the enhancement of CNS 
depressants action by Y-23684 was weaker than that of di-
azepam [375]. Behavioral profiles in the mouse defence test 
battery confirmed Y-23684 anxiolytic potential that was 
comparable to that of BZs in the MDTB [376].  
 
 
Fig. (72). Chemical structure of Y-23684. 
 
Most recently the development of selective brain-
penetrating GABAC receptor antagonists is of particular in-
terest [377]. In this group of compounds there are conforma-
tionally restricted analogs of the orally active GABAB/C re-
ceptor antagonist (3-aminopropyl)-n-butylphosphinic acid 
(CGP36742 or SGS742) (Fig. 73). These cis- and trans-(3-
aminocyclopentanyl)butylphosphinic acids (cis- and trans-3-
ACPBPA) are highly potent and selective for 1 GABAC 
receptors, being greater than 100 times more potent at 
GABAC than GABAA receptors and 50 times more potent at 
GABAC than GABAB receptors. These compounds showed 
potential use in sleep disorders, preventing the development 
of experimental myopia. Additionally, the substances en-
hanced learning and memory in rats [378, 379]. 
 
Fig. (73). Chemical structure of CGP36742 or SGS742. 
 
Fig. (74). Chemical structures of cis-3-ACPBPA and trans-3-
ACPBPA. 
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3. CONCLUSIONS 
This review shows that there is a significant progress in 
understanding etiopathogenesis and molecular biology also 
in CNS diseases, which have been a major challenge for dec-
ades. However, drug discovery process seems too slow to 
provide specific ligands for ion channels/receptors subtypes. 
Many receptors subtypes lack a ligand, and if an effect of 
agonism/antagonism would be beneficial, this fact indicates 
a strong need for drug discovery in this field.  
Currently, many old drugs are tested for their potential 
use in diseases which are still defined as “unmet need”. This 
in turn implies side effects, which are rarely positive, as in 
the case of dihydropyridine derivatives binding to CaV2.1 
(P/Q) channels. In most cases of drugs the side effects are 
negative, and this together with effectiveness of old drugs in 
new diseases, is the greatest premise for drug development in 
novel subtypes of receptors. Nifedipine can serve as an ex-
ample of an old drug, which on one hand could prevent from 
Parkinson’s disease, and on the other hand – it diminishes 
anticonvulsant activity of topiramate.  
Ion channels have been biological targets for the first 
synthesized drugs (e.g. phenytoin, carbamazepine, diaze-
pam). Therefore, they seemed unattractive for some pharma-
ceutical companies, seeing no use in developing a “me-too” 
drug. However, this review shows that understanding of 
mechanisms and discovery of subtypes of ion channels may 
increase their involvement in therapies in the future (with 
some exceptions, of course, e.g. CaV2.1 channels). CNS dis-
eases, which are particularly hard to treat, are waiting to be 
managed, and we hope to have proved that this process is 
possible with use of novel ion channels ligands developed by 
the pharmaceutical market. 
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